(i) Were observational studies analyzing the longitudinal association between anxiety or depression (disorders as well as symptom severity) and QoL,
(ii) Analyzed samples without a specific disease or disorder other than anxiety and depression,
(iii) Applied appropriate, validated measures for the main variables (e.g., for anxiety/depression: psychiatric diagnosis according to criteria of the International Classification of Diseases (ICD), the Diagnostic and Statistical Manual of Mental Disorders (DSM), or using a valid self-report screening tool), and
(iv) Were published in English or German in a peer-reviewed journal.
Abbreviations: QoL = quality of life; ICD = International Classification of Diseases; DSM = Diagnostic and Statistical Manual of Mental Disorders; BL = study baseline; KIDSCREEN = Health Related Quality of Life Questionnaire for Children and Young People and their Parents; KINDL = German generic quality of life instrument for children
We extracted information regarding the study design, operationalization of the variables, sample characteristics, statistical methods and results regarding the research question of interest. If several analyses were presented for the same research question, we extracted the final covariate-adjusted model for narrative synthesis. Data were extracted by one reviewer (J.K.H.) and cross-checked by a second reviewer (E.Q.). If needed, extracted data were standardized (e.g., by calculating the weighted average means when combining groups) to present comparable information. If clarification was needed, the corresponding authors were contacted.
For the narrative synthesis, all studies were first grouped by research question, e.g., whether disorders or the degree of symptoms were analyzed, which comparison groups were used, which QoL domains were considered, and at which waves the variables of interest were considered in the analyses. Because research questions and analyses were heterogeneous, a concise narrative synthesis of the main results of all studies was not feasible. Therefore, we provide an overview of all identified studies in the tables and a detailed narrative synthesis of those studies, analyzing trajectories of disorders or changes in symptoms in association with changes in QoL over time.
Additionally, we examined whether data were appropriate for meta-analysis. The specific research questions, the operationalization of main variables and statistical methods were heterogeneous across studies and not all the statistical estimates needed could be obtained from covariate-adjusted analyses. Therefore, to enhance the comparability of the underlying data and the interpretation of the pooled estimates, we used descriptive information. Because most papers applied variations of the Short Form Health Survey and analyzed mental and physical component scores (MCS, PCS), we considered these studies as eligible for meta-analysis. The necessary information could be obtained for 8 publications. Random-effects meta-analysis was used for pooling. Heterogeneity was assessed by means of I 2 , with higher values representing a larger degree of heterogeneity in terms of variability in effect size estimates between studies [ 41 ]. Pooled estimates are reported as Hedge’s g standardized mean difference (SMD), representing the difference in mean outcomes between groups relative to outcome measure variability [ 42 ]. According to Cohen (as cited in [ 43 ]), SMDs can be grouped into small ≤0.20, medium = 0.50 and large effects ≥0.80. Stata 16 was used for meta-analyses.
Two reviewers (J.K.H., E.Q.) independently assessed the quality and risk of bias of the included studies using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, which was developed by the National Heart, Lung, and Blood Institute [ 44 ].
The literature search yielded 4027 unique references. After title/abstract screening, 215 studies were included for full-text screening. Finally, 47 publications were included in the final synthesis. During full-text screening, most studies were excluded because they exclusively analyzed data on a cross-sectional level (56.5%). For further details, see the PRISMA flow chart ( Figure 1 ).
Descriptive characteristics and quality/risk of bias assessment of the included studies are provided in Table S1 (Supplementary Material) . In short, sample size ranged from 28 to 43,093. Most studies focused on adults; only four analyzed children/adolescents. Regarding the settings, 17 of the analyzed samples were exclusively recruited in a health care setting, 12 of the studies analyzed general population samples, 14 recruited in another or in several settings, and all studies on children/adolescents recruited in schools ( n = 4). Twenty studies (42.6%) applied data from the same seven underlying datasets. Most studies reported on depression ( n = 36), less reported on anxiety ( n = 20) and some reported on the comorbidity between depression and anxiety ( n = 7). To assess mental disorders, half (48.9%) used structured interviews. Regarding QoL, most studies applied variations of the Short Form Health Survey (SF, n = 27) or the WHOQOL ( n = 12). A total of 38.3% of the studies were rated as “good”, 55.3% as “fair” and 6.4% as “poor” in the quality assessment.
Detailed results on all studies investigating the association between anxiety/depression as independent variables and QoL outcomes are reported in Table 2 . As described in the methods section, the following paragraphs give an overview of those studies focusing on disorder trajectories/changes in symptoms over time and changes in QoL outcomes over time, because they allow for more differentiated interpretations.
Studies on depression/anxiety as independent variables and QoL outcomes.
First Author (Year) | Disorder or Symptoms Analyzed; QoL Domains Analyzed | Research Question Regarding QoL | Methods | Results |
---|---|---|---|---|
Årdal (2013) [ ] | Controls and patients in the acute phase of recurrent MD and FU (DSM-IV, HDRS); SF-36 (physical functioning, role physical, vitality, bodily pain, mental health, role emotional, social functioning, general health, as well as summary scores PCS, MCS and total score) | (a) Whether QoL scores differ between MD patients and healthy comparisons across domains over time. (b) Whether QoL in patients with recurrent MDD differed between acute phase and recovery. | (a) ANOVA (b) Paired-sample -tests | (a) There was a significant interaction effect between time, QoL domain and group, indicating that QoL scores differed between MD patients and controls over time. Compared to the healthy control group, the MDD group had reduced QoL in all domains at BL and reduced QoL in several domains at FU (significant for general health, social, emotional role, mental health, PCS, MCS and total score). (b) In the MD group, QoL scores significantly improved during recovery from recurrent MDD in most domains (significant for physical functioning, physical role, vitality, social functioning, role emotional, mental health, PCS, MCS and total score). |
Buist-Bouwman (2004) [ ] | Onset, acute phase and subsequent remission from MDE (CIDI); comorbid anxiety disorder (CIDI); SF-36 (physical functioning, physical role, vitality, pain, psychological health, psychological role, social functioning and general health) | (a) Whether incident MDE and recovery from MDE are associated with changes in QoL and whether pre- and post-morbid QoL scores in the MD group differ from the comparison group without MD. (b) In the subgroup with worse QoL after MDE: whether the severity of depression and number of depressive episodes were associated with worse QoL. (c) Whether comorbid anxiety during MDE is associated with reduced QoL (i.e., lower QoL after MDE compared to before MDE). | (a)–(c) Multivariate logistic regression | (a) Incident MDE was associated with a drop in QoL (significant for vitality, psychological, psychological role and social functioning). Subsequent recovery from MDE was associated with an improvement in QoL (significant for physical role, vitality, psychological health, psychological role, social functioning and general health). Comparing pre- and post-morbid levels, QoL did not differ or was higher after MDE in some domains (significantly higher for psychological health and psychological role). Moreover, before MD onset, QoL was significantly lower compared to healthy controls in all domains. After remission from MDE, QoL scores in nearly all domains (not significant for psychological role) were significantly lower compared to healthy controls. (b) About 40% of the MDE group had worse QoL after recovery from MDE compared to pre-morbid levels. The severity of depression was associated with worse QoL only for the psychological health domain, but no other domains. The number of depressive episodes was not significantly associated with worsening QoL in any domain. (c) In the MDE cohort, comorbid anxiety was associated with a significant reduction in QoL (significant for physical role and psychological health). |
Cabello (2014) [ ] | Chronic MD (AUDADIS interview; summary score of the number of symptoms to identify severity); SF-12, “disability” (i.e., domain-specific reduced QoL, defined as score ≤ 25th percentile in the subscale; physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role and mental health) | (a) Whether chronic MD is associated with the incidence/persistence of “disability” (i.e., reduced QoL) in a general population sample. (b) Whether the severity of depressive symptoms is associated with the incidence/persistence of “disability” (i.e., reduced QoL) in the MD subgroup of the sample. | Both (a) and (b) Generalized Estimating Equations and logistic regressions | (a) In the general population, chronic MD was a significant risk factor for the persistence of disability (i.e., reduced QoL) in all domains and of the incidence of disability (i.e., reduced QoL) in all domains except for the physical role. (b) In the chronic MD subgroup, the severity of depressive symptoms was associated with the persistence of disability (i.e., reduced QoL) (significant for general health, social functioning, emotional role and mental health) and not significantly associated with the incidence of reduced QoL in any domain. |
Cerne (2013) [ ] | Number of depressive episodes over time according to CIDI; number of episodes of panic and other anxiety syndromes over time (PHQ); SF-12 (PCS, MCS) | Whether the pooled number of (a) depressive episodes over time, (b) panic and anxiety episodes over time are are associated with the pooled QoL over time. | (a) and (b) Multivariate linear regression | (a) A higher number of depressive episodes over time was associated with lower pooled PCS and MCS. (b) a higher number of pooled panic episodes over time was associated with a lower mean MCS but not PCS. A higher number of pooled other anxiety syndrome episodes over time was not associated with the mean MCS or PCS. |
Chin (2015) [ ] | Depression according to PHQ-9 (>9), clinician’s diagnosis; SF-12v2 (PCS, MCS) | (a) Whether depressive symptoms and a clinician’s detection of depression at BL are associated with QoL at FU. (b) Whether a clinician’s detection of depression at BL is associated with a change in QoL. | (a) Multivariable non-linear mixed-effects regression (b) Independent -tests | (a) Depressive symptoms and a clinician’s detection of depression at BL were not predictive of QoL at FU. (b) A clinician’s detection of depression at BL was related to change (improvement) in MCS, but not PCS over time in a primary care sample screened as positive for depression. |
Chung (2012) [ ] | Depression diagnosis and symptoms (DSM-IV, HRSD depression scale, HADS depression scale); anxiety symptoms (HRSD anxiety scale, HADS anxiety scale; SF-36 (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental health, PCS and MCS) | (a) Whether BL depressive symptoms are associated with QoL at FU. (b) Whether BL depressive symptoms or changes in depressive symptoms are associated with changes in QoL over time. (c) Whether BL anxiety symptoms are associated with QoL at FU. (d) Whether BL anxiety symptoms or changes in anxiety symptoms are associated with changes in QoL over time. | (a)–(d) Hierarchical regression | (a) BL depressive symptoms were not associated with any QoL domain at FU. (b) BL depressive symptoms were not associated with changes in any QoL domain over time. Changes in depressive symptoms were significantly associated with changes in some QoL domains over time (significant for: general health, vitality, mental health and MCS). (c) BL anxiety symptoms were not associated with any QoL domain at FU. (d) BL anxiety symptoms were not associated with changes in any QoL domain over time. Changes in anxiety symptoms were significantly associated with changes in some QoL domains over time (significant for: bodily pain, general health and mental health). |
Diehr (2006) [ ] | Depression according to CIDI, CES-D (>16); QLDS, WHOQOL-Bref (environmental, physical, psychological and social), SF-12 (PCS, MCS) | (a) Whether the quartile of change in depressive symptoms is associated with changes in QoL. (b) Whether the remission of depression at FU is associated with changes in QoL. | Regression | (a) No/little change in CES-D associated with changes in QoL over time (significant for SF-12 MCS). Every other quartile of change in depressive symptoms was significantly associated with changes in QoL in most scales/domains (significant for: QLDS, all domains of WHOQOL-Bref and SF-12 MCS), meaning a higher reduction in depressive symptoms was associated with a higher increase in QoL, and more severe depressive symptoms were associated with a reduction in QoL. (b) Remission of depression at FU was associated with improvement in all QoL measures and domains (SF-12, QLDS and WHOQOL-Bref). There was no significant change in QoL in those with persistent clinical depression at FU. |
Hajek (2015) [ ] | Depressive symptoms (GDS); EQ-VAS | Whether an initial change in depressive symptoms is associated with a subsequent change in QoL in the whole sample and by sex. | Vector autoregressive models | No significant association between an initial change in depression score and a subsequent change in QoL was found for the whole sample or stratified by sex. |
Hasche (2010) [ ] | Depression status at BL (according to DIS diagnosis and CES-D ≥ 9); SF-8 (PCS, MCS) | (a) Whether depression status groups at BL differed according to QoL at FU. (b) Whether depression status groups at BL differed according to QoL changes in score over time. | (a) -tests (b) Linear mixed effects regression models | (a) At 6- and 12-month FU, those with and without depression at BL differed significantly in QoL scores, with the depression group reporting lower QoL at FUs (significant for MCS and PCS). (b) While depression at BL was significantly related to improvements in MCS (but not PCS) scores over time, those with depression still reported lower QoL compared to those without. |
Heo (2008) [ ] | Depression (BDI ≥ 10); SF-36 (decrease in total score over time) | Whether FU depression is associated with a reduction in QoL over time. | Binary logistic regression | Depression at FU was associated with a significant reduction in QoL total score over time. |
Ho (2014) [ ] | Depression (according to GDS ≥ 5); SF-12 (PCS, MCS) | Whether depression at BL is associated with QoL at FU. | Linear regression | BL depression was associated with lower QoL at FU (significant for MCS and PCS). |
Hussain (2016) [ ] | Depressive disorders (SCID, MINI); current PTSD, specific phobias, other anxiety disorders (SCID, MINI); WHOQOL-Bref (general QoL and hrqol) | (a) Whether current depressive disorders at BL predict QoL at FU. (b) Whether current PTSD, specific phobias and other anxiety disorders at BL predict QoL at FU. | (a) and (b) Multiple linear regression | (a) Depressive disorders at BL predicted reduced QoL at FU (significant for general QoL and hrqol). (b) PTSD, but not specific phobias or other anxiety disorders, predicted reduced general QoL at FU. None of the anxiety disorders predicted hrqol at FU. |
Joffe (2012) [ ] | Lifetime history of depression (according to SCID); anxiety disorder (according to SCID); SF-36 (impaired QoL according to 25th percentile of SF-36; social functioning, role emotional, role physical, pain and vitality) | (a) Whether a lifetime history of depression is associated with impaired QoL during FU. (b) Whether a prior lifetime history of anxiety disorder (compared to no depression or anxiety) is associated with reduced QoL during FU. (c) Whether a lifetime history of comorbid depression and anxiety is associated with impaired QoL during FU. | (a)–(c) Repeated measure multilevel regression | (a) A history of depression only was associated with reduced QoL during FU (significant for social functioning and pain). (b) Prior lifetime history of anxiety disorder was associated with reduced QoL (significant for physical role). (c) A history of comorbid anxiety and depression was associated with reduced QoL during FU (significant for social functioning, emotional role, physical role and pain). |
Johansen (2007) [ ] | Level of PTSD symptoms according to IES-15; WHOQOL-Bref (physical health, psychological health, social relationships and environment) | Whether PTSD symptoms predict QoL at FU. | Structural equation model | More severe PTSD symptoms predicted QoL at FU (significant positive association between FU1 and FU2). |
Kramer (2003) [ ] | Current or lifetime depression/PTSD (according to Q-DIS); SF-36 (energy/fatigue, emotional role, general health, mental health, pain, physical functioning, physical role and social) | Whether QoL outcomes over time differed among the disorder groups. | Random/fixed effects model | There was no significant interaction between time and diagnostic group (no depression/PTSD, PTSD, depression and comorbid depression/PTSD) on QoL. Comparing the adjusted means for all three times among the disorder groups showed significant differences between the groups in most domains. In comparison, those with depression at BL reported reduced QoL over time in several domains compared to the PTSD group and the group without PTSD/depression. In comparison, those with PTSD only showed higher QoL compared to those with depression or comorbid depression/PTSD in several domains. |
Kuehner (2009) [ ] | Depressive symptoms (MADRS); WHOQOL (overall, physical, psychological, social and environmental) | Whether the lag in levels of depressive symptoms predicts future levels of QoL and whether the association differs by group (formerly depressed inpatients vs. community controls). | Time-lagged linear models | Higher depressive symptoms predict future lower QoL (significant for social). The association was not moderated by group status. |
Kuehner (2012) [ ] | Depression score (according to MADRS, FDD-DSM-IV); WHOQOL-Bref (physical, psychological, social and environment) | Whether the lag in depressive symptoms predicted QoL at FU. | Hierarchical, time-lagged linear models | Higher depressive symptoms significantly predicted lower QoL at FU (significant for physical and psychological). |
Lenert (2000) [ ] | Remission or persistent depression (according to DSM-III criteria, DIS); SF-12 (PCS, MCS) | Whether the remission of depression (compared to no remission) is associated with changes in QoL over time. | OLS regression | Remission of depression was associated with improved QoL (significant for MCS) at FU1 and FU2. |
Mars (2015) [ ] | Asymptomatic, mild and high symptoms of depression (according to SCAN); EQ-5D (without anxiety/depression item) | Whether depression symptom trajectories over time (asymptomatic, mild symptoms and chronic–high symptoms) are associated with QoL at FU. | Latent class growth analysis with distal outcome models | QoL at FU differed significantly among different depression symptom trajectories, with persons from the the chronic–high depressive symptom class showing lower QoL scores relative to the asymptomatic class. |
Moutinho (2019) [ ] | Depression at BL (according to DASS cut-off: 9); anxiety at BL (according to DASS anxiety scale cutoff: 7); WHOQOL-Bref at FU (physical, psychological, social and environment) | (a) Whether BL depression predicted QoL at FU. (b) Whether BL anxiety predicted QoL at FU. | (a) and (b) Stepwise linear regression | (a) Depression at BL was significantly associated with reduced QoL at FU (significant for psychological functioning, social functioning and environmental). (b) Anxiety at BL was associated with reduced QoL at FU (significant for physical). |
Ormel (1999) [ ] | Depression at BL (according to CIDI); “disability” (i.e., reduced QoL according MOS SF 6-item physical functioning scale ≥ 2) | Whether depression at BL is associated with the onset of disability (i.e., reduced QoL) during FU. | Logistic regression models | Compared to the non-depressed group, people with depression at BL showed higher odds for the onset of disability (i.e., reduced QoL) during FU (significant for 12-month FU, but not 3-month FU). |
Pan (2012) [ ] | Depressive symptoms (CES-D); WHOQOL-Bref-TW (overall score, physical, psychological, social and environmental) | Whether depressive symptoms were associated with QoL over time. | Linear mixed-effects models | Higher depressive symptoms were associated with lower QoL in MDD patients (significant for overall score, physical, psychological, social and environmental). |
Panagioti (2018) [ ] | Depressive symptoms (MHI-5); WHOQOL-Bref (physical, psychological, environmental and social) | Whether depressive symptoms at BL are associated with changes in QoL over time. | Multivariate regression models | Higher depressive symptoms at BL were associated with a decline in QoL over time (significant for physical and psychological). |
Pakpour (2018) [ ] | Dental anxiety at BL (MDAS); PedsQL 4.0 general hrqol and oral hrqol scale at FU | Whether dental anxiety at BL predicted oral- and general-health-related QoL at FU. | Structural equation modeling | Dental anxiety at BL was no significant direct predictor of generic QoL at FU and was significantly associated with worse oral-health-related QoL at FU. |
Pyne (1997) [ ] | MD-diagnosis (SCID/SADS) and depressive symptoms (HAM-D); QWB | Whether group status over time (community controls, continuously non-depressed patients, incident depression patients and continuously depressed patients) is associated with changes in QoL. | Repeated measure analysis (ANOVA) | There was no significant interaction term between group status and time, indicating that changes in QoL did not differ between the groups. At both points in time, QoL differed significantly among all groups, except between the incident depression and continuous depression group. |
Remmerswaal (2020) [ ] | OCD course (SCID), Y-BOCS, BDI, BAI over time; EQ-5D over time | (a) Whether OCD symptom severity and QoL over time were associated. (b) Whether QoL over time differs between OCD course groups (chronic, intermittent and remitting) and general population norms. (c) Whether OCD symptom severity, anxiety and depressive symptoms over time are associated with changes in QoL over time in patients with OCD. | (a) Pearson’s correlation (b)–(c) Linear mixed models | (a) QoL over time and OCD symptom severity were significantly correlated. (b) The QoL of OCD patients was significantly lower compared to general population norms, except the QoL of the intermittent OCD group at FU1, where there was no significant difference compared to the general population. When comparing the OCD course groups, the chronic OCD group had a significantly lower QoL over time compared to the other groups. The remitting group had moderately improved until FU1 and a small QoL improvement between FU1 and FU2 relative to the chronic group. (c) In those with a remitting OCD, only more severe symptoms of comorbid anxiety and depressive symptoms, but not OCD symptom severity over time, were significantly associated with a lower QoL over time. |
Rhebergen (2010) [ ] | MD-/dysthymia-/DD diagnosis at BL and subsequent recovery at FU (according to CIDI); comorbid anxiety at BL (CIDI); SF-36 (physical health summary score) | Whether QoL trajectories over time differ between: (a) different depression status groups who achieved remission (MDD, dysthymia and double depression) and a comparison group without mental health disorders. (b) The different depression status groups. (c) Whether comorbid anxiety at BL in a sample recovering from depression is associated with changes in QoL. | (a)–(c) Linear mixed models | (a) There was a significant interaction between group status and time. More specifically, compared to changes in QoL over time in people without a mental health diagnosis, QoL improved over time in those with MDD and DD, but not dysthymia. All depression diagnosis groups showed a significantly lower QoL compared to the no diagnosis group at all waves. (b) Considering the depression groups, only the interaction term between dysthymia and time until FU1 was significant. Those with dysthymia had a significantly lower QoL compared to those with MDD at FU1. This difference was not significant at FU2. (c) Comorbid anxiety disorder at BL in people who recovered from depression over time was not associated with a significant change in QoL over time. |
Rubio (2014) [ ] | First episode of incident MDD (AUDADIS-IV) at FU; incident GAD, social anxiety disorder, PD, specific phobia (AUDADIS-IV); SF-12 (MCS) | Whether incident MDD is associated with changes in QoL over time compared to: (a) people without history of MDD, (b) without history of any mental health disorder, (c) and whether the association differed by gender. Whether incident anxiety disorders are associated with changes in QoL over time: (d) compared to no history of the specific anxiety disorder, (e) compared to no history of any psychiatric disorder, (f) and whether the association differed by gender. | Linear regression model | (a) Incidence of MDD (compared to no MDD) was associated with a significant decrease in QoL until FU. (b) Incidence of MDD (compared to no mental health disorder) was associated with a significant decrease in QoL until FU. (c) The association did not vary by gender. (d) Incidence of all anxiety disorders (with comorbid disorders; ref: no history of anxiety disorder) was associated with a significant decrease in QoL over time. (e) Incident anxiety disorders were not significantly associated with QoL when only considering “pure” anxiety without any comorbidities (ref: no history of any psychiatric disorder). (f) The association did not vary by gender. |
Rubio (2013) [ ] | Remission from MDD, dysthymia (AUDADIS-IV); Remission from GAD, PD, SAD, specific phobia (AUDADIS-IV); SF-12 (MCS) | Whether remission from depression (MDD, dysthymia) is associated with: (a) changes in QoL over time (compared to non-remitted cases), (b) QoL at FU (compared to people with no history of a specific depressive disorder), (c) QoL at FU, when only considering depressive disorders without any psychiatric comorbidity (compared to people without any lifetime psychiatric diagnosis). Whether remission from anxiety disorders are associated with: (d) changes in QoL over time (compared to non-remitted cases), (e) QoL at FU (compared to people with no history of a specific anxiety disorder), (f) QoL at FU, when only considering anxiety disorders without any psychiatric comorbidity (compared to people without any lifetime psychiatric diagnosis). | (a)–(f) Linear regression models | (a) Remission from MD and dysthymia was associated with a significant positive change in QoL compared to non-remitted cases. (b) Remission of MD and dysthymia was associated with significantly lower QoL at FU compared to people without history of a specific diagnosis. (c) Remission of MD and dysthymia was associated with significantly lower QoL at FU compared to people without any lifetime psychiatric diagnosis. (d) Remission from SAD and GAD was associated with significant positive changes in QoL compared to non-remitted cases. (e) Remission of PD, SAD, specific phobia and GAD was associated with significantly lower QoL at FU compared to people without history of a specific diagnosis. (f) Remission of “pure” PD, SAD, specific phobias and GAD was associated with significantly lower QoL at FU compared to people without any lifetime psychiatric diagnosis. |
Rozario (2006) [ ] | Depressive symptoms (GDS); SF-12 (MCS and PCS) | Whether depressive symptom severity was associated with QoL change profiles over time (no change, declined and improved groups). | Multinomial logistic regression | There was no significant association between depressive symptom severity and QoL change score profiles at FU. |
Sareen (2013) [ ] | Depression trajectory groups over time (according to AUDADIS-IV); anxiety disorder trajectory groups over time (according to AUDADIS-IV); SF-12 (MCS and PCS) | (a) Whether depression trajectory groups (no past year disorder/no suicide attempt at FU, remission without treatment, persistent disorder/comorbidity/suicide attempt/treatment) differed according to QoL at FU. (b) Whether anxiety disorder trajectory groups (no past year disorder/no suicide attempt at FU, remission without treatment, persistent disorder/comorbidity/suicide attempt/treatment) differed according to QoL at FU. | (a) and (b) Multiple linear regression models | (a) QoL at FU differed among the different depression trajectory groups (MCS was significant for all groups: no disorder > remitted disorder > persistent disorder; PCS: no disorder > remitted disorder; remitted disorder < persistent disorder). (b) QoL at FU differed among the different anxiety trajectory groups (MCS was significant for all groups: no disorder > remitted disorder > persistent disorder; PCS: no disorder > persistent disorder, remitted disorder > persistent disorder). |
Shigemoto (2020) [ ] | PTSD symptoms (PCL-C); Q-LES-Q (psychosocial and physical) | Whether previous PTSD symptoms are associated with QoL at FU. | Longitudinal structural equation model | Previous PTSD symptoms were associated with physical QoL at FU1, but not FU2 or psychosocial QoL at both FUs. |
Siqveland (2015) [ ] | Depressive symptoms (according to the depression scale from the GHQ-28); PTSD symptoms (PCL-S); WHOQOL-Bref (global and hrqol) | (a) Whether depressive symptoms at BL are associated with QoL at FU. (b) Whether PTSD symptoms at BL are associated with QoL at FU. | (a) and (b) Multiple mixed effects regression analyses | (a) Higher depressive symptoms at BL were associated with reduced QoL at FU. (b) PTSD levels at BL were not significantly associated with reduced QoL at FU. |
Spijker (2004) [ ] | Depression status (CIDI); Comorbid anxiety (CIDI); SF-36 (social, role emotional) | (a) Whether depression status over time (non-depressed, recovered or depressed (including persistent, relapsing course)) is associated with QoL at FU. Whether comorbid anxiety is associated with QoL at FU (b) in a group with persistent depression and (c) in a group recovered from depression. | ANOVA | (a) QoL at FU was significantly reduced in depressed samples compared to the non-depressed group, and lower in the persistently depressed compared to the recovered group (significant for: role emotional and social). Among the depressed subgroups, there was no significant difference between a persistent or a relapsing course regarding QoL at FU. (b) In the persistently depressed group, comorbid anxiety was significantly associated with reduced QoL at FU (significant for role emotional and social). (c) In those who recovered from depression, comorbid anxiety was significantly associated with reduced QoL (significant for role emotional). |
Stegenga (2012) [ ] | MDD status according to CIDI (remitted, intermittent and chronic); SF-12 (PCS and MCS) | Whether MDD course (remitted, intermittent and chronic) is associated with QoL over time. | Random coefficient analysis | While change in QoL over time did not differ between course groups, QoL at BL (MCS) was lower in those with a chronic course compared to those who remitted from BL. |
Stegenga (2012) [ ] | MDD (CIDI); anxiety syndromes (panic disorder and others, PHQ); SF-12 (PCS) | (a) Whether MDD at BL predicts change in QoL over time. (b) Whether anxiety syndrome at BL (compared to no psychiatric diagnosis) predict changes in QoL over time. (c) Whether comorbid anxiety and MDD at BL (compared to no psychiatric diagnosis) predict changes in QoL over time. | (a)–(c) Random coefficient model | (a) While changes in QoL over time did not differ significantly between those with MDD at BL and those without any psychiatric diagnosis, QoL at BL was lower in those with depression. (b) While changes in QoL over time did not differ significantly between those with anxiety syndrome at BL and those without any psychiatric diagnosis, QoL at BL was lower in those with anxiety compared to those without any psychiatric diagnosis. (c) While changes in QoL over time did not differ significantly between those with comorbid anxiety and MDD at BL and those without any psychiatric diagnosis, QoL at BL was lower in those with comorbid anxiety and MDD compared to those without any psychiatric diagnosis. |
Stevens (2020) [ ] | Posttraumatic stress symptoms (VETR-PTSD); SF-36 (MCS, PCS, physical functioning, bodily pain, general health, role physical, role emotional, mental health, vitality and social functioning) | Whether PTSS at BL is associated with QoL at FU. | Generalized estimating equations | Higher BL PTSS was significantly associated with lower QoL (PCS and MCS) at FU. Using a Bonferroni-corrected alpha value, only the domains of mental health, vitality and social functioning at FU were significantly associated with BL PTSS symptoms. The interaction between time and PTSS at BL was not significant, indicating that PTSS had the same effect on QoL outcomes at both FUs. |
Tsai (2007) [ ] | Increased post-traumatic stress symptoms (DRPST); MOS SF-36 (physical functioning, role physical, pain, general health, vitality, social functioning, role emotional, mental health, PCS and MCS) | (a) Whether different PTSS trajectory groups over time (persistent PTSS, recovered, delayed and persistently healthy) differed in QoL at FU. (b) Whether increased post-traumatic stress symptoms at BL predicted QoL at FU. | (a) ANOVA (b) Multiple regression models | (a) At FU, those who were persistently healthy had the highest QoL scores (significantly higher compared to the persistent group in all domains; significantly higher than the recovered group for: pain, general health, vitality, mental health and MCS; significantly higher compared to delayed PTSS in all domains). In addition, those with delayed PTSS (significantly lower than the recovered group in all domains except physical functioning) and those with persistent PTSS (significantly lower than recovered group in all domains) had the lowest QoL overall. (b) Increased PTSS at BL was not significantly associated with QoL at FU. |
Vulser (2018) [ ] | Depressive symptom levels (CES-D score), depression status (CES-D ≥ 19); SF-12v2 (role emotional and social) | Whether depressive symptoms or depression status at BL are associated with QoL at FU. | Generalized linear models | Both the level of depressive symptoms at BL as well as depression status at BL were associated with QoL at FU (significant for: role emotional and social). |
Wang (2000) [ ] | Depressive symptoms (SCL-90 subscale); anxiety symptoms (SCL-90 subscale); WHOQOL-Bref (total) | (a) Whether depressive symptoms at BL were associated with QoL at FU. (b) Whether anxiety symptoms at BL were associated with QoL at FU. | (a) and (b) Stepwise regression | (a) Higher depressive symptoms at BL were associated with reduced QoL at FU. (b) Anxiety symptoms BL were not included in the final stepwise regression model. |
Wang (2017) [ ] | Depressive disorder course groups (CIDI); anxiety disorder course (CIDI); SF-36 (MCS, PCS) | (a) Whether QoL at FU differs between three different course groups of depressive disorders (1. no disorder at BL and no suicide attempt until FU; 2. remitted without treatment; 3. persistent disorder/treatment/developed psychiatric co-morbidity/suicide attempt until FU). (b) Whether QoL at FU differs between three different course groups of anxiety disorders (1. no disorder at BL and no suicide attempt until FU; 2. remitted without treatment; 3. persistent disorder/treatment/developed psychiatric co-morbidity/suicide attempt until FU). | (a) and (b) Multiple linear regression | (a) Those with depression at BL that remitted without treatment had lower QoL at FU (significant for MCS and PCS) than those without the disorder and higher QoL at FU (significant for MCS) than those with a persistent disorder. (b) Those with anxiety at BL that remitted without treatment over time had lower QoL at FU than those without the disorder and higher QoL (MCS, but not PCS) than those with a persistent disorder. |
Wu (2015) [ ] | Depressive symptoms according to CDI; social anxiety symptoms (SASC); QOLS | (a) Whether depressive symptoms at BL are associated with QoL at FU. (b) Whether social anxiety symptoms at BL are associated with QoL at FU. | (a) and (b) Multivariate stepwise forward regression | (a) Higher depressive symptoms at BL were significantly associated with reduced QoL at FU. (b) Higher social anxiety symptoms at BL were not significantly associated with QoL at FU. |
Abbreviations: QoL = quality of life; MD = major depression; FU = follow-up; DSM = Diagnostic and Statistical Manual of Mental Disorders; HDRS = Hamilton Depression Rating Scale; PCS = Physical Component Score; MDS = Mental Component Score; MDD = major depressive disorder; ANOVA = analysis of variance; BL = baseline; MDE = major depressive episode; CIDI = Composite International Diagnostic Interview; SF-36 = Short Form 36; AUDADIS = Alcohol Use Disorders and Associated Disabilities Interview Schedule; SF-12 = Short Form 12; PHQ = Patient Health Questionnaire; SF-12v2: Short Form 12, Version 2; HRSD = Hamilton Rating Scale for Depression; HADS = Hospital Anxiety and Depression Scale; QLDS = Quality of Life in Depression Scale; EQ-VAS = EQ Visual Analogue Scale; DIS = Diagnostic Interview Schedule; BDI = Beck Depression Inventory; SCID = Short Children’s Depression Inventory; MINI = Mini-International Neuropsychiatric Interview; PTSD = post-traumatic stress disorder; hrqol = health-related quality of life, IES-15 = Impact of Event Scale 15; Q-DIS = Quick Version of the Mental Health’s Diagnostic Interview Schedule; MADRS = Montgomery–Åsberg Depression Rating Scale; FDD-DSM-IV = Fragebogen zur Depressionsdiagnostik nach Diagnostic and Statistical Manual of Mental Disorders IV; SCAN = Schedule for Clinical Assessment in Neuropsychiatry; DASS = Depression Anxiety Stress Scales; MOS SF = Medical Outcomes Study Short Form; CES-D = Center for Epidemiological Studies Depression Scale; WHOQOL-Bref-TW = WHOQOL-Bref Taiwan Version; MHI-5 = Mental Health Inventory 5; OCD = obsessive compulsive disorder; Y-BOCS = Yale–Brown Obsessive Compulsive Scale; BAI = Beck Angst Inventar; DD = depressive disorder; PD = psychiatric disorder; SAD = social anxiety disorder; Q-LES-Q = Quality of Life Enjoyment and Satisfaction Questionnaire; GHQ-28 = General Health Questionnaire 28; PCL-S = Post-traumatic Stress Disorder Checklist Scale; VETR-PTSD = Vietnam Era Twin Registry Posttraumatic Stress Disorder; DRPST = Disaster-Related Psychological Screening Test; SCL-90 = Symptomcheckliste bei psychischen Störungen 90; SASC = SpLD Assessment Standards Committee; QOLS = Quality of Life Scale; CDI = Children’s Depression Inventory.
Depression as independent variable and QoL as outcome. One study investigated QoL at several time points during the entire course of an episode of MD .
Buist-Bouwman, Ormel, de Graaf and Vollebergh [ 46 ] analyzed an MD group from a general population setting (NEMESIS) with data on SF-36 domains in the onset, acute and recovery phase of the depressive episode. The onset of MD was associated with a significant drop in several QoL domains and recovery with a significant increase. Pre- and post-morbid QoL levels were not significantly different for most domains, and post-morbid QoL was even higher for the psychological role functioning and psychological health domains. In comparison to a group without MD, pre- and post-morbid QoL levels in the MD group were significantly lower, except for the psychological role functioning domain, where no significant differences were found. Additionally, it should be noted that 40% of the sample had lower post-morbid QoL compared to pre-morbid levels.
Two studies investigated changes in QoL for people experiencing an onset of depression relative to different comparison groups over two points in time.
One study investigated incident MD in a general population sample (NESARC; Rubio, Olfson, Perez-Fuentes, Garcia-Toro, Wang and Blanco [ 14 ]). Here, incident MD (compared to those without a history of MD as well as to a group without any mental disorder) was associated with a significant drop in QoL (SF-12 MCS). Additionally, analyzing two waves, Pyne, Patterson, Kaplan, Ho, Gillin, Golshan and Grant [ 67 ] compared the QoL (Quality of Well-Being scale) between MD patients and community controls. The patient group was further divided into those continuously not receiving an MD diagnosis, those who continuously received the diagnosis and those who only received the diagnosis at FU (onset). The authors found that changes in QoL did not differ between the groups. At both points in time, QoL scores differed significantly between the groups, except for the incident and the continuous depression group [ 67 ].
Six studies investigated different courses of depression over time in people with depression at BL with or without a healthy comparison group as reference.
Two primary care studies analyzed groups with clinical depression at BL with different FU depression statuses (remission, no remission). One study [ 51 ] analyzed changes in generic QoL measures (SF-12, WHOQOL-Bref) and the disease-specific Quality of Life in Depression Scale. In this study, remission was associated with an improvement in all QoL domains, whereas QoL did not change significantly over time for the non-remitted group. Another study [ 60 ] investigated SF-12 MCS and PCS scores and reported a significant increase in MCS over time in the remitting group. MCS scores in the continuously depressed group and PCS scores in both groups improved, albeit not significantly.
Another study [ 47 ] investigated whether chronic MD in a general population sample (NESARC) was associated with domain-specific reduced QoL (SF-12). They found that chronic MD was a significant risk factor for persistently reduced QoL in all domains and for the onset of reduced QoL at FU in all domains except for physical role.
Two population-based studies further differentiated between the depressive disorders. Analyzing MCS scores (NESARC), Rubio, Olfson, Villegas, Perez-Fuentes, Wang and Blanco [ 15 ] reported a significant increase in QoL for those who remitted from MD and from dysthymia relative to those who had a persistent disorder. Rhebergen, Beekman, de Graaf, Nolen, Spijker, Hoogendijk and Penninx [ 69 ] differentiated between people with MD, double depression or dysthymia at BL who remitted until FU relative to a group without a mental health diagnosis (NEMESIS). Physical health (SF-36) was lowest at BL for double depression, dysthymia and then the MD group. Over time, the MD and double depression groups improved significantly in their physical health, while the dysthymia group did not improve significantly. QoL was significantly lower relative to healthy comparisons for all depression groups at all waves. There were no significant differences regarding physical health trajectories over time among the depressive disorder groups.
Stegenga, Kamphuis, King, Nazareth and Geerlings [ 75 ] investigated more than two MD course groups over time (remitted, intermittent and chronic MD) in association with SF-12 MCS and PCS over time in a primary care-recruited sample with BL MD (Predict study). MCS increased over time in all groups, while changes in PCS were small. Compared to those who remitted, MCS at BL was significantly lower for the chronic course group. While the intermittent group also displayed a lower mean MCS at BL, the coefficient was not significant.
Three studies investigated changes in depressive symptom levels as the independent variable and changes in QoL as outcomes in adults.
One study found no significant association between an initial change in depressive symptoms and subsequent change in QoL (EQ-VAS) in older adults recruited in primary care [ 21 ]. The two other studies analyzed changes in depressive symptoms in samples with MD at BL [ 50 , 51 ]. Chung, Tso, Yeung and Li [ 50 ] found that changes in depressive symptom levels was associated with changes in several QoL domains (SF-36: general health, vitality, social functioning, mental health and MCS). Diehr, Derleth, McKenna, Martin, Bushnell, Simon and Patrick [ 51 ] investigated whether quartiles of change in depressive symptoms were associated with changes in QoL (SF-12, QLDS and WHOQOL-Bref). Those without any change in depressive symptoms generally showed no change in QoL. For all QoL domains and scores except for SF-12 PCS, improvement in depressive symptoms over time was associated with a significant increase in QoL, while a reduction in depressive symptoms was associated with a significant reduction in QoL. Those who had the largest reduction in depressive symptoms also had the largest improvement in QoL measures.
Anxiety as an independent variable and QoL as an outcome. Two publications used a general population sample (NESARC) to investigate incident anxiety disorders [ 14 ] and the remission of anxiety disorders [ 15 ] in association with SF-12 MCS. Both studies separated generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder (PD) and social phobia (SP). All incident disorders were associated with a significant reduction in QoL compared to people without a history of the specific disorders. When the analysis was restricted to incident cases without comorbidities, QoL levels were not significantly different compared to people without a history of any psychiatric disorder [ 14 ]. Those who remitted from SAD showed a significant increase in QoL compared to persistent cases. While QoL improved for all remitting anxiety disorders, change scores for PD and SP were not significant [ 15 ].
Another study investigated different courses (intermittent, chronic or remitting) of obsessive compulsive disorder (OCD) and course in QoL (EQ-5D) as well as a comparison group from the general population [ 68 ]. They found that the OCD groups mostly reported a lower QoL compared to the general population. Moreover, the course groups differed regarding their QoL over time, with remitters reporting small to moderate improvements compared to the chronic group.
One study investigated changes in anxiety symptoms in association with changes in all SF-36 domains and both summary scores over time in a sample with MD at BL [ 50 ]. Changes in anxiety symptoms were significantly associated with changes in bodily pain, general health and the mental health domain.
Additionally, we identified publications operationalizing QoL as the independent variable and anxiety/depression as outcomes with details on all studies reported in Table 3 . Only one study reported on change in QoL over time and change/trajectories in mental health outcomes over time. This study operationalized change in QoL as a predictor of future change in depressive symptoms over time and reported that an initial improvement in EQ-VAS was associated with a future reduction in depressive symptoms in older adults [ 21 ].
Studies on QoL as the independent variable and depression/anxiety as outcome.
First Author (Year) | Disorder or Symptoms Analyzed; QoL Domains Analyzed | Research Question | Methods | Results |
---|---|---|---|---|
Chou (2011) [ ] | Depressive sympt oms (CES-D-20 score); WHOQOL-Bref (total) | Whether QoL at BL is associated with depressive symptoms at FU. | Multiple regression | Lower QoL at BL was associated with higher depressive symptoms at FU. |
De Almeida Fleck (2005) [ ] | Depression status (remission vs. no complete remission, CIDI and CES-D-20 cutoff >16); QLDS, WHOQOL-Bref (physical, psychological, social and environment), SF-12 (PCS, MCS) | Whether QoL at BL is associated with course of depression (complete remission vs. non-complete remission) in a depressed sample. | Stepwise multiple logistic regression | Disease-specific QoL measure at BL significantly predicted the remission of depression at FU (significant for QLDS). |
Hajek (2015) [ ] | Depressive symptoms (GDS); EQ-VAS | Whether an initial change in QoL is associated with subsequent changes in depressive symptoms. | Vector autoregressive model | Initial changes in QoL were associated with a subsequent reduction in depression score (significant for total sample and women). |
Hoertel (2017) [ ] | MD (according to AUDADIS-IV): SF-12v2 (PCS and MCS) | Whether QoL at BL predicted recurrence (vs. remission) or persistence (vs. remission) of MD over time. | Structural equation model | Lower QoL at BL was a predictor of risk of persistence (PCS and MCS) and recurrence of MDE over time. |
Johansen (2007) [ ] | PTSD symptoms according to IES-15; WHOQOL-Bref (total) | Whether QoL predicted PTSD symptoms at FU. | Structural equation model | QoL did not significantly predict PTSD symptoms at FU. |
Kuehner (2009) [ ] | Depressive symptoms (MADRS); WHOQOL (overall, physical, psychological, social and environmental) | Whether the lag of levels of QoL predicts future levels of depressive symptoms and whether the association differs by group (formerly depressed inpatients vs. community controls) | Time-lagged linear models | Lower levels of QoL were associated with higher future depressive symptoms (significant for physical, psychological, environmental and overall). The association was not moderated by group status. |
Stegenga (2012) [ ] | MDD (CIDI); anxiety syndromes (panic disorder and others, PHQ); SF-12 (PCS) | (a) Whether “dysfunction” (i.e., reduced QoL) at BL (mildly reduced, moderately reduced or severely reduced; compared to no reduced QoL) predicts MDD onset over time. (b) Whether “dysfunction” (i.e., reduced QoL) at BL (mildly reduced, moderately reduced or severely reduced; compared to no reduced QoL) predicts anxiety syndrome onset over time. (c) Whether “dysfunction” (i.e., reduced QoL) at BL (mildly reduced, moderately reduced or severely reduced; compared to no reduced QoL) predicts onset of comorbid anxiety and MDD over time. | (a)–(c) Multinomial logistic regressions | (a) Dysfunction (i.e., reduced QoL) at BL was associated with higher odds of onset of MDD over time in the sample of people without a diagnosis at BL (significant for severely reduced QoL). (b) Dysfunction (i.e., reduced QoL) at BL was associated with higher odds of onset of anxiety syndrome over time in the sample of people without a diagnosis at BL (significant for moderately and severely reduced QoL). (c) Dysfunction (i.e., reduced QoL) at BL was associated with higher odds of onset of comorbid anxiety and depression over time in the sample of people without a diagnosis at BL (significant for mild, moderately and severely reduced QoL). |
Wu (2016) [ ] | Elevated social anxiety symptoms (SASC cutoff 9); QOLS | Whether QoL is associated with changes in elevated social anxiety symptoms over time. | Generalized Estimating Equation | Higher QoL was associated with a decreased risk for developing elevated social anxiety symptoms over time. |
Wu (2017) [ ] | Elevated depressive symptoms (according to CDI ≥19); QOLS | Whether QoL at BL is associated with elevated depressive symptoms at FU. | Multiple stepwise logistic regression | QoL at BL was not significantly related to depressive symptoms at FU. |
Abbreviations: CES-D-20 = Center for Epidemiological Studies Depression Scale 20; BL = baseline; FU = follow-up; QoL = quality of life; CIDI = Composite International Diagnostic Interview; QLDS = Quality of Life in Depression Scale; SF-12 = Short Form 12; PCS = Physical Component Score; MCS = Mental Component Score; GDS = Geriatric Depression Scale; EQ-VAS = EQ Visual Analogue Scale; MD = mental disorder; AUDADIS-IV = Alcohol Use Disorders and Associated Disabilities Interview Schedule; SF-12v2 = Short Form 12 Version 2; PTSD = post-traumatic stress disorder; IES-15 = Impact of Event Scale 15; MADRS = Montgomery–Åsberg Depression Rating Scale; MDD = major depressive disorder; PHQ = Patient Health Questionnaire; SASC = SpLD Assessment Standards Committee; QOLS = Quality of Life Scale; CDI = Children’s Depression Inventory.
In total, eight studies on adults were included in a supplementary meta-analyses of several research questions on SF PCS and MCS in association with anxiety and depressive disorders. Forest plots for the analyses are provided in the supplementary materials (Figures S1–S10) .
Differences in SF summary scores at FU among adults with and without depressive disorders at BL. Based on a pooling of four studies [ 45 , 49 , 52 , 54 ], those with depression at BL showed lower MCS scores at FU compared to a group without depression at BL with a large effect size (SMD = −0.96, 95% CI: −1.04 to −0.88, p < 0.001, I 2 = 0.0%). PCS scores at FU were lower for the depression group compared to the non-depression group with a medium effect size (SMD = −0.68, 95% CI: −1.06 to −0.30, p < 0.001, I 2 = 94.6%). Excluding the study rated “poor” in the quality/risk of bias assessment from the pooling did not substantially affect the results (MCS: SMD = −0.96, 95% CI: −1.03 to −0.88, p < 0.001, I 2 = 0.01%; PCS: SMD = −0.63, 95% CI: −1.08 to −0.19, p < 0.01, I 2 = 96.8%).
BL differences in SF summary scores among adults with MD at BL with and without remitting courses over time. Based on a pooling of two studies [ 19 , 84 ] of samples with MD at BL, those with persistent MD at FU had significantly lower MCS at BL (SMD = −0.25, 95% CI: −0.41 to −0.10, p = 0.001, I 2 = 74.95) and PCS scores at BL (SMD = −0.24, 95% CI: −0.39 to −0.09, p = 0.002, I 2 = 73.14) compared to those who achieved remission until FU. Effect sizes were small for both summary scores.
FU differences in SF summary scores among adults with depressive and anxiety disorders at BL with and without remitting courses . Based on the pooling of two studies [ 71 , 81 ] of samples with MD and/or dysthymia, the group where the disorder had persisted/a co-morbid condition was present/had a suicide attempt until FU had significantly lower MCS scores at FU compared to the group where the disorder had remitted without treatment until FU, with a medium effect size for depressive disorders (SMD = −0.59, 95% CI: −0.75 to −0.42, p < 0.001, I 2 = 37.72) and a small effect size for anxiety disorders (SMD = −0.44, 95% CI: −0.58 to −0.30, p < 0.001, I 2 = 58.87). The SMD for PCS scores at FU was negligible in terms of effect size for both disorder groups (depressive disorders: SMD = 0.02, 95% CI: −0.24 to 0.27, p = 0.90, I 2 = 73.65; anxiety disorders: SMD = −0.09, 95% CI: −0.17 to −0.01, p = 0.03, I 2 = 0.01).
4.1. main results.
This review adds to the present literature by providing an overview of longitudinal observational studies investigating the association between depression, anxiety and QoL in samples without other specific illnesses or specific treatments. Additional meta-analyses investigated group differences according to SF MCS and PCS.
While a concise synthesis of all the identified studies is challenging due to heterogeneity, the following picture emerges from studies investigating change–change associations: before the onset of disorders, QoL is already lower in disorder groups in comparison to healthy comparisons. The onset of the disorders further reduces the QoL. Remission is associated with an increase in QoL, mostly to pre-morbid levels. Additionally, some studies show that remission patterns are relevant for QoL outcomes as well. Moreover, a bi-directional effect was reported, whereby QoL is also predictive of mental health outcomes.
Evidence for a bi-directional association as well as studies showing lower QoL across the entire course of the disorders (before onset, during disorder, after disorder) relative to a healthy comparison group seem to suggest that impairments in QoL may result from a certain pre-disorder vulnerability in these groups. Longitudinal studies using general population data have investigated different hypotheses on (QoL) impairments after remission of anxiety disorders and MD [ 87 , 88 ]. One hypothesis suggests that impairments after the illness episode reflect a pre-disorder vulnerability (vulnerability or trait hypothesis), while the another states that impairments develop during the mental health episode and remain as a residual after recovery (scar hypothesis). Generally, both studies favored the vulnerability hypothesis [ 87 , 88 ]. For subgroups with recurrent anxiety disorders, scarring effects were also found for mental functioning [ 88 ]. Yet, it has to be noted that it was not the aim of our review to gather evidence for these hypotheses using QoL as an indicator, which represents an opportunity for future research.
To be able to investigate possible domain-specific differences across studies, we aimed to conduct a meta-analysis on all studies on the same research question which reported on QoL subdomains (e.g., using WHOQOL and SF). However, as described in the Methods section above, only eight studies reported comparable information on different research questions and could be included in meta-analyses. Due to the limited number of studies included in each meta-analysis, the focus on SF MCS and PCS scores, and most studies reporting on depression, the results of the meta-analyses should be viewed with caution. Keeping this in mind, our results indicate that both mental and physical QoL are significantly impacted by anxiety and depressive disorders and that the course of the disorder is also relevant for QoL outcomes. Not surprisingly, effect sizes for MCS were larger compared to PCS for most research questions. A pooling of two studies on different courses of anxiety and depressive disorders found that effect sizes for MCS at FU were of moderate size for depressive (SMD = −0.59) and of small size for anxiety disorders (SMD = −0.44), while SMDs for PCS at FU were negligible in size.
Overall, effect sizes from meta-analyses ranged from negligible to large, and heterogeneity varied considerably (I 2 between 0% and 95%). Because of the small number of studies, possible influential study-level factors (e.g., setting, operationalization of the variables, length of FU) could not be investigated in further detail by means of a meta-regression, which remains a question for future research.
Based on the results described and study heterogeneity discussed above, we provide recommendations for future research.
First recommendation: future research should differentiate between individual disorders and focus on anxiety disorders. The majority of the studies investigated depressive disorders or symptoms. On the level of individual disorders, most focused on MD, while two studies additionally reported on dysthymia [ 15 , 69 ]. One of these investigated double depression [ 69 ]. On the level of anxiety disorders, three publications differentiated between individual anxiety disorders within the same study [ 14 , 15 , 63 ]. While it was not possible to conduct a meta-analysis comparing different anxiety disorders in our case, individual studies suggest possible disorder-specific differences when analyzing changes in QoL over time: Rubio, Olfson, Villegas, Perez-Fuentes, Wang and Blanco [ 15 ] suggest that QoL significantly improved for those remitting from GAD and SAD (compared to non-remission). QoL improved for PD and SP as well, but differences in change scores were smaller and did not reach statistical significance. The incidences of all of these disorders were associated with a significant drop in QoL [ 14 ]. In summary, future longitudinal studies should focus on anxiety disorders and generally differentiate between individual disorders to investigate possible disorder-specific differences.
Second recommendation: future research should consider trajectories of disorders/change in symptoms and changes in QoL over time. We would have liked to include a meta-analysis of disorder trajectories and change scores in QoL over time. Because of the small, diverse number of studies on this association in general and the number of assumptions that would have had to have been made for a meta-analysis, we refrained from pooling effects for this research question. In total, 17 studies investigated changes in independent variables associated with changes in outcomes. This approach has several advantages. On the one hand, different disorder or symptom trajectories can be identified. Several studies reported that QoL outcomes differ according to disorder course and the degree of change in symptoms. The focus on the change in characteristics over time in future research could additionally reduce the problem of unobserved time-constant heterogeneity in observational studies when appropriate methods are applied [ 26 ].
Third recommendation: future research should investigate individual QoL domains. Several systematic reviews on cross-sectional studies found that effect sizes differed by QoL domains [ 32 , 89 ]. For example, Olatunji, Cisler and Tolin [ 89 ] reported that health and social functioning were most impaired for anxiety disorders (compared to non-clinical controls). Comparing individuals with diabetes and depressive symptoms to those with diabetes only, Schram, Baan and Pouwer [ 32 ] reported that while SF pain scores were mild to moderately impaired, role and social functioning displayed moderate to severe impairments in those with comorbid depressive symptoms. The other scores were moderately impaired. As described above in detail, a meta-analysis using all subdomains was not feasible in this review. Further research differentiating between QoL domains would thus allow future meta-analyses to investigate whether the observed domain-specific differences reported in previous reviews of cross-sectional data can be observed in longitudinal studies as well.
Fourth recommendation: future research should consider bi-directional effects. While investigating QoL as the outcome measure and anxiety/depression as independent variables seems relatively straightforward, ten studies investigated QoL as the independent variable and anxiety/depression as outcomes. In light of possible bi-directional effects and pre-existing vulnerability suggested by individual studies, future research considering QoL as an independent variable could inform a deeper understanding of this complex association.
A strength of this work is the transparent methodological process: the review was prospectively registered with PROSPERO and a study protocol was published [ 34 ]. Two reviewers were included in screening, data extraction and quality assessment processes. There were no limitations regarding the time or location of the publications. Moreover, all versions of the ICD/DSM and validated questionnaires were considered eligible to identify anxiety or depression. Another strength is the thorough literature search that enabled us to identify all relevant studies. Additionally, we did not limit the age range and were therefore able to shed light on studies investigating children/adolescents. Moreover, some studies could be pooled using random-effects meta-analyses, which allows for stronger conclusions regarding effect sizes compared to individual studies. Besides the content analysis, this review emphasizes difficulties in meta-analysis from observational, longitudinal studies. We hope that our work can facilitate discussion on this topic.
The study has some limitations. We did not limit our search to specific research questions, which led to the inclusion of heterogeneous studies. Heterogeneity particularly stemmed from the operationalization of the variables of interest. Due to this, a concise narrative synthesis of all results was not feasible. The positive aspect of this broad focus is that it allowed us to provide an overview of studies and research questions analyzed and to formulate more nuanced recommendations for future research. We have to acknowledge that there is an abundance of QoL assessments used in medicine and health sciences [ 37 ]. The list applied in this work was derived with respect to previous relevant reviews on QoL research. It was not designed to be fully comprehensive or exhaustive. Rather, it provided us with a working definition for this review and helped to enhance the transparency of our selection processes. Additionally, because we included validated QoL measures frequently used in research, we assume that exclusion would particularly have been the case for novel or study-specific measures. Finally, the focus on peer-reviewed literature means that studies in other languages and gray literature were not considered. Nonetheless, this focus on literature published in peer-reviewed journals should ensure a certain scientific quality.
Overall, the results indicate that QoL is lower before the onset of anxiety and depressive disorders, further reduces upon onset of the disorders and generally improves with remission to pre-morbid levels. Moreover, disorder course (e.g., remitted, intermittent, chronic) seems to play an important role; however, only a few studies analyzed this. Changes in anxiety and depressive symptoms were also associated with changes in QoL over time. Meta-analyses found that effect sizes were larger for MCS relative to PCS, highlighting the relevance of differentiation between QoL domains. While our review identified some gaps in the current literature and made recommendations for future research, the following should be noted for clinical practice. On the one hand, an improvement in mental health is associated with better QoL, which emphasizes the relevance of support during the disorders. This is also shown by meta-analyses, which show that cognitive behavioral therapy additionally improves QoL [ 90 , 91 ]. Moreover, the results indicate reduced QoL even before disorder onset, highlighting the relevance of early preventive measures in vulnerable groups. In line with this, studies on school-based prevention programs show a significant reduction in anxiety and depressive symptoms [ 92 , 93 ], and psychosocial prevention programs may additionally improve QoL [ 94 ].
During the COVID-19 pandemic, it is of high relevance to tackle the arising challenges associated with this pandemic. For example, it is important to face the high prevalence rates of both depression and anxiety with appropriate measures.
The authors would like to thank Elzbieta Kuzma for her consultation (Albertinen-Haus Centre for Geriatrics and Gerontology, University of Hamburg, Hamburg, Germany; University of Exeter Medical School, Exeter, UK).
The following are available online at https://www.mdpi.com/article/10.3390/ijerph182212022/s1 , Table S1: detailed descriptive information for included studies ( n = 47); Figure S1: forest plot for differences in SF MCS at FU among adults with and without depressive disorders at BL; Figure S2: forest plot for differences in SF PCS at FU among adults with and without depressive disorders at BL; Figure S3: forest plot for differences in SF MCS at FU among adults with and without depressive disorders at BL (sensitivity analysis); Figure S4: forest plot for differences in SF PCS at FU among adults with and without depressive disorders at BL (sensitivity analysis); Figure S5: forest plot for BL differences in SF MCS among adults with MD at BL with and without remitting courses over time; Figure S6: forest plot for BL differences in SF PCS among adults with MD at BL with and without remitting courses over time; Figure S7: forest plot for FU differences in SF MCS among adults with depressive disorders at BL with and without remitting courses; Figure S8: forest plot for FU differences in SF PCS among adults with depressive disorders at BL with and without remitting courses; Figure S9: forest plot for FU differences in SF MCS among adults with anxiety disorders at BL with and without remitting courses; Figure S10: forest plot for FU differences in SF PCS among adults with anxiety disorders at BL with and without remitting courses.
J.K.H.: conceptualization of research question; development of search strategy; study screening and selection; risk of bias/quality assessment; study synthesis; writing—original draft, review and editing; H.-H.K.: conceptualization of research question; writing—review and editing; E.Q.: study screening and selection; risk of bias/quality assessment; writing—review and editing; A.H.: conceptualization of research question; development of search strategy; study screening and selection (third party); study synthesis; writing—review and editing. All authors have read and agreed to the published version of the manuscript.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data availability statement, conflicts of interest.
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Evolution and emerging trends in depression research from 2004 to 2019: a literature visualization analysis.
Depression has become a major threat to human health, and researchers around the world are actively engaged in research on depression. In order to promote closer research, the study of the global depression knowledge map is significant. This study aims to map the knowledge map of depression research and show the current research distribution, hotspots, frontiers, and trends in the field of depression research, providing researchers with worthwhile information and ideas. Based on the Web of Science core collection of depression research from 2004 to 2019, this study systematically analyzed the country, journal, category, author, institution, cited article, and keyword aspects using bibliometric and data visualization methods. A relationship network of depression research was established, highlighting the highly influential countries, journals, categories, authors, institutions, cited articles, and keywords in this research field. The study identifies great research potential in the field of depression, provides scientific guidance for researchers to find potential collaborations through collaboration networks and coexistence networks, and systematically and accurately presents the hotspots, frontiers, and shortcomings of depression research through the knowledge map of global research on depression with the help of information analysis and fusion methods, which provides valuable information for researchers and institutions to determine meaningful research directions.
Health issues are becoming more and more important to people due to the continuous development of health care. The social pressures on people are becoming more and more pronounced in a social environment that is developing at an increasing rate. Prolonged exposure to stress can have a negative impact on brain development ( 1 ), and depression is one of the more typical disorders that accompany it. Stress will increase the incidence of depression ( 2 ), depression has become a common disease ( 3 ), endangering people's physical health. Depression is a debilitating mental illness with mood disorders, also known as major depression, clinical depression, or melancholia. In human studies of the disease, it has been found that depression accounts for a large proportion of the affected population. According to the latest data from the World Health Organization (WHO) statistics in 2019, there are more than 350 million people with depression worldwide, with an increase of about 18% in the last decade and an estimated lifetime prevalence of 15% ( 4 ), it is a major cause of global disability and disease burden ( 5 ), and depression has quietly become a disease that threatens hundreds of millions of people worldwide.
Along with the rise of science communication research, the quantification of science is also flourishing. As a combination of “data science” and modern science, bibliometrics takes advantage of the explosive growth of research output in the era of big data, and uses topics, authors, publications, keywords, references, citations, etc. as research targets to reveal the current status and impact of the discipline more accurately and scientifically. Whereas, there is not a wealth of bibliometric studies related to depression. Fusar-Poli et al. ( 6 ) used bibliometrics to systematically evaluate cross-diagnostic psychiatry. Hammarström et al. ( 7 ) used bibliometrics to analyze the scientific quality of gender-related explanatory models of depression in the medical database PubMed. Tran et al. ( 8 ) used the bibliometric analysis of research progress and effective interventions for depression in AIDS patients. Wang et al. ( 9 ) used bibliometric methods to analyze scientific studies on the comorbidity of pain and depression. Shi et al. ( 10 ) performed a bibliometric analysis of the top 100 cited articles on biomarkers in the field of depression. Dongping et al. ( 11 ) used bibliometric analysis of studies on the association between depression and gut flora. An Chunping et al. ( 12 ) analyzed the literature on acupuncture for depression included in PubMed based on bibliometrics. Yi and Xiaoli ( 13 ) used a bibliometric method to analyze the characteristics of the literature on the treatment of depression by Chinese medicine in the last 10 years. Zhou and Yan ( 14 ) used bibliometric method to analyze the distribution of scientific and technological achievements on depression in Peoples R China. Guaijuan ( 15 ) performed a bibliometric analysis of the interrelationship between psoriasis and depression. Econometric analysis of the relationship between vitamin D deficiency and depression was performed by Yunzhi et al. ( 16 ) and Shauni et al. ( 17 ) performed a bibliometric analysis of domestic and international research papers on depression-related genes from 2003 to 2007. A previous review of depression-related bibliometric studies revealed that there is no bibliometric analysis of global studies in the field of depression, including country network analysis, journal network analysis, category network analysis, author network analysis, institutional network analysis, literature co-citation analysis, keyword co-presentation analysis, and cluster analysis.
The aim of this study was to conduct a comprehensive and systematic literature-based data mining and metrics analysis of depression-related research. More specifically, this analysis focuses on cooperative network and co-presentation analysis, based on the 36,477 papers included in the Web of Science Core Collection database from 2004 to 2019, and provides an in-depth analysis of cooperative network, co-presentation network, and co-citation through modern metrics and data visualization methods. Through the mining of key data, the data correlation is further explored, and the results obtained can be used to scientifically and reasonably predict the depression-related information. This study aims to show the spatial and temporal distribution of research countries, journals, authors, and institutions in the field of depression in a more concise manner through a relational network. A deeper understanding of the internal structure of the research community will help researchers and institutions to establish more accurate and effective global collaborations, in line with the trend of human destiny and globalization. In addition, the study will allow for the timely identification of gaps in current research. A more targeted research direction will be established, a more complete picture of the new developments in the field of depression today will be obtained, and the research protocol will be informed for further adjustments. The results of these analyses will help researchers understand the evolution of this field of study. Overall, this paper uses literature data analysis to find research hotspots in the field of depression, analyze the knowledge structure within different studies, and provide a basis for predicting research frontiers. This study analyzed the literature in the field of depression using CiteSpace 5.8.R2 (64-bit) to analyze collaborative networks, including country network analysis, journal network analysis, category network analysis, researcher network analysis, and institutional network analysis using CiteSpace 5.8.R2 (64-bit). In addition, literature co-citation, keyword co-presentation, and cluster analysis of depression research hotspots were also performed. Thus, exploring the knowledge dimensions of the field, quantifying the research patterns in the field, and uncovering emerging trends in the field will help to obtain more accurate and complete information. The large amount of current research results related to depression will be presented more intuitively and accurately with the medium of information technology, and the scientific evaluation of research themes and trend prediction will be provided from a new perspective.
The data in this paper comes from the Web of Science (WoS) core collection. The time years were selected as 2004–2019. First, the literature was retrieved after entering “depression” using the title search method. A total of 73,829 articles, excluding “depression” as “suppression,” “decline,” “sunken,” “pothole,” “slump,” “low pressure,” “frustration.” The total number of articles with other meanings such as “depression” was 5,606, and the total number of valid articles related to depression was 68,223. Next, the title search method was used to search for studies related to “major depressive disorder” not “depression,” and a total of 8,070 articles were retrieved. For the two search strategies, a total of 76,293 records were collected. The relevant literature retrieved under the two methods were combined and exported in “plain text” file format. The exported records included: “full records and references cited.” CiteSpace processed the data to obtain 41,408 valid records, covering all depression-related research articles for the period 2004–2019, and used this as the basis for analysis.
CiteSpace ( 18 ), developed by Chao-Mei Chen, a professor in the School of Information Science and Technology at Drexel University, is a Java-based program with powerful data visualization capabilities and is one of the most widely used knowledge mapping tools. The software version used in this study is CiteSpace 5.8.R2 (64-bit).
This study uses bibliometrics and data visualization as analytical methods. First, the application of bibliometrics to the field of depression helped to identify established and emerging research clusters, demonstrating the value of research in this area. Second, data visualization provides multiple perspectives on the data, presenting correlations in a clearer “knowledge graph” that can reveal underestimated and overlooked trends, patterns, and differences ( 19 ). CiteSpace is mainly based on the “co-occurrence clustering idea,” which extracts the information units (keywords, authors, institutions, countries, journals, etc.) in the data by classification, and then further reconstructs the data in the information units to form networks based on different types and strengths of connections (e.g., keyword co-occurrence, author collaboration, etc.). The resulting networks include nodes and links, where the nodes represent the information units of the literature and the links represent the existence of connections (co-occurrence) between the nodes. Finally, the network is measured, statistically analyzed, and presented in a visual way. The analysis needs to focus on: the overall structure of the network, key nodes and paths. The key evaluation indicators in this study are: betweenness centrality, year, keyword frequency, and burst strength. Betweenness centrality (BC) is the number of times a node acts as the shortest bridge between two other nodes. The higher the number of times a node acts as an “intermediary,” the greater its betweenness centrality. Betweenness centrality is a measure of the importance of articles found and measured by nodes in the network by labeling the category (or authors, journals, institutions, etc.) with purple circles. There may be many shortest paths between two nodes in the network, and by counting all the shortest paths of any two nodes in the network, if many of the shortest paths pass through a node, then the node is considered to have high betweenness centrality. In CiteSpace, nodes with betweenness centrality over 0.1 are called critical nodes. Year, which represents the publication time of the article. Frequency, which represents the number of occurrences. Burst strength, an indicator used to measure articles with sudden rise or sudden decline in citations. Nodes with high burst strength usually represent a shift in a certain research area and need to be focused on, and the burst article points are indicated in red. The nodes and their sizes and colors are first analyzed initially, and further analyzed by betweenness centrality indicators for evaluation. Each node represents an article, and the larger the node, the greater the frequency of the keyword word and the greater the relevance to the topic. Similarly, the color of the node represents time: the warmer the color, the more recent the time; the colder the color, the older the era; the node with a purple outer ring is a node with high betweenness centrality; the color of each annual ring can determine the time distribution: the color of the annual ring represents the corresponding time, and the thickness of one annual ring is proportional to the number of articles within the corresponding time division; the dominant color can reflect the relative concentration of the emergence time; the node The appearance of red annual rings in the annual rings means hot spots, and the frequency of citations has been or is still increasing rapidly.
Country analysis.
During the period 2004–2019, a total of 157 countries/territories have conducted research on depression, which is about 67.38% of 233 countries/territories worldwide. This shows that depression is receiving attention from many countries/regions around the world. Figure 1 shows the geographical distribution of published articles for 157 countries. The top 15 countries are ranked according to the number of articles published. Table 1 lists the top 15 countries with the highest number of publications in the field of depression worldwide from 2004 to 2019. These 15 countries include 4 Asian countries (Peoples R China, Japan, South Korea, Turkey), 2 North American countries (USA, Canada), 1 South American country (Brazil), 7 European countries (UK, Germany, Netherlands, Italy, France, Spain, Sweden), and 1 Oceania country (Australia).
Figure 1 . Geographical distributions of publications, 2004–2019.
Table 1 . The top 15 productive countries.
Overall, the main distribution of these articles is in USA and some European countries, such as UK, Germany, Netherlands, Italy, France, Spain, and Sweden. This means that these countries are more interested and focused on research on depression compared to others. The total number of publications across all research areas in the Web of Science core collection is similar to the distribution of depression research areas, with the trend toward USA, UK, and Peoples R China as leading countries being unmistakable, and USA has been a leader in the field of depression, with far more articles published than any other country. It can also be seen that USA is the country with the highest betweenness centrality in the network of national collaborations analyzed in this paper. USA research in the field of depression is closely linked to global research, and is an important part of the global collaborative network for depression research. As of 2019, the total number of articles published in depression performance research in USA represents 27.13% of the total number of articles published in depression worldwide, which is ~4 times more than the second-place country, UK, which is far ahead of other countries. Peoples R China, as the third most published country, has a dominant number of articles, but its betweenness centrality is 0.01, reflecting the fact that Peoples R China has less collaborative research with other countries, so Peoples R China should strengthen its foreign collaborative research and actively establish global scientific research partnerships to seek development and generate breakthroughs in cooperation. The average percentage of scientific research on depression in each country is about 0.19%, also highlighting the urgent need to address depression as one of the global human health problems. The four Asian countries included in the top 15 countries are Peoples R China, Japan, South Korea, and Turkey, with Peoples R China ranking third with 6.72% of the total number of all articles counted. The distribution may be explained by the fact that Peoples R China is the largest developing country with a rapid development rate as the largest. Along with the steady rise in the country's economic power, people are creating economic benefits and their health is becoming a consumable commodity. The lifetime prevalence and duration of depression varies by country and region ( 2 ), but the high prevalence and persistence of depression worldwide confirms the increasing severity of the disease worldwide. The WHO estimates that more than 300 million people, or 4.4% of the world's population, suffer from depression ( 20 ), with the number of people suffering from depression increasing at a patient rate of 18.4% between 2005 and 2015. Depression, one of the most prevalent mental illnesses of our time, has caused both physical and psychological harm to many people, and it has become the leading cause of disability worldwide today, and in this context, there is increased interest and focus on research into depression. It is expected that a more comprehensive understanding of depression and finding ways to prevent and cope with the occurrence of this disease can help people get rid of the pain and shadow brought by depression, obtain a healthy and comfortable physical and mental environment and physical health, and make Chinese contributions to the cause of human health. Undoubtedly, the occurrence of depressive illnesses in the context of irreversible human social development has stimulated a vigorous scientific research environment on depression in Peoples R China and other developing countries and contributed to the improvement of research capacity in these countries. Moreover, from a different perspective, the geographical distribution of articles in this field also represents the fundamental position of the country in the overall scientific and academic research field.
Figure 2 depicts the distribution of 38,433 articles from the top 10 countries in terms of the number of publications and the trend of growth during 2004–2019.
Figure 2 . The distribution of publications in top 10 productive countries, 2004–2019. Source: author's calculation. National development classification criteria refer to “Human Development Report 2020” ( 21 ).
First, the number of articles published per year for the top 10 countries in terms of productivity was counted and then the white bar chart in Figure 2 was plotted, with the year as the horizontal coordinate and total publications as the vertical coordinate, showing the distribution of the productivity of articles in the field of depression per year. The total number of publications for the period 2004–2019 is 38,433. Based on the white bars and line graphs in Figure 2 , we can divide this time period into three growth periods. The number of publications in each growth period is calculated based on the number of publications per year. As can be seen from the figure, the period 2004–2019 can be divided into three main growth periods, namely 2004–2009, 2010–2012, and 2013–2019, the first growth period being from 2004 to 2009, the number of publications totaled 6,749, accounting for 23.97% of all publications; from 2010 to 2012, the number of publications totaled 8,236, accounting for 17.56% of all publications; and from 2013 to 2019, the number of publications totaled 22,473, accounting for 58.47% of all publications. Of these, 2006 was the first year of sharp growth with an annual growth rate of 19.97%, 2009 was the second year of sharp growth with an annual growth rate of 17.64%, and 2008 was the third year of sharp growth with an annual growth rate of 16.09%. In the last 5 years, 2019 has also shown a sharp growth trend with a growth rate of 14.34%. Notably, in 2010 and 2013, there was negative growth with the growth rate of −3.39 and −1.45%. In the last 10 years, depression research has become one of the most valuable areas of human research. It can also be noted that the number of publications in the field of depression in these 10 countries has been increasing year after year.
Second, the analysis is conducted from the perspective of national development, divided into developed and developing countries, as shown in the orange bar chart in Figure 2 , where the horizontal coordinate is year and the vertical coordinate is total publications, comparing the article productivity variability between developed and developing countries. The top 10 most productive countries in the field of depression globally include nine developed countries and one developing country, respectively. During the period 2004–2019, 34,631 papers were published in developed countries and 3,802 papers were published in developing countries, with developed countries accounting for 90.11% of the 38,433 articles and developing countries accounting for 9.89%, and the total number of publications in developed countries was about 9 times higher than that in developing countries. During the period 2004–2019, the number of publications in developed countries showed negative growth in 2 years (2010 and 2013) with growth rates of −3.39 and −1.45%, respectively. The rest of the years showed positive growth with growth rates of 1.52% (2005), 19.97 (2006), 8.11 (2007), 12.70 (2008), 17.64 (2009), 13.22 (2011), 10.17 (2012), 16.09 (2014), 10.46 (2015), 4.10 (2016), 1.59 (2017), 3.91 (2018), and 14.34 (2019), showing three periods of positive growth: 2004–2009, 2011–2012, and 2014–2019, with the highest growth rate of 19.97% in 2006. Recent years have also shown a higher growth trend, with a growth rate of 14.34% in 2019. It is worth noting that developing countries have been showing positive growth in the number of articles in the period 2004–2019, with annual growth rates of 81.25 (2005), 17.24 (2006), 35.29 (2007), 19.57 (2008), 65.45 (2009), 13.19 (2010), 29.13 (2011), 54.89 (2012), 12.14 (2013), 36.36 (2014), 14.92 (2015), 16.02 (2016), 10.24 (2017), 21.17 (2018), and 31.37 (2019), with the highest growth rate of 81.25% in 2005. In the field of depression research, developed countries are still the main force and occupy an important position.
Further, 10 countries with the highest productivity in the field of depression are compared, total publications in the vertical coordinate, and the colored scatter plot contains 10 colored dots, representing 10 different countries. On the one hand, the variability of the contributions of different countries in the same time frame can be compared horizontally. On the other hand, it is possible to compare vertically the variability of the growth of different countries over time. Among them, USA, with about 40.29% of the world's publications in the field of depression, has always been a leader in the field of depression with its rich research results. Peoples R China, as the only developing country, ranks 3rd in the top 10 countries with high production of research papers in the field of depression, and Peoples R China's research in the field of depression has shown a rapid growth trend, and by 2016, it has jumped to become the 2nd largest country in the world, with the number of published papers increasing year by year, which has a broad prospect and great potential for development.
Table 2 lists the top 15 journals in order of number of journal co-citations. In the field of depression, the top 15 cited journals accounted for 19.06% of the total number of co-citations, nearly one in five of the total number of journal co-citations. In particular, the top 3 journals were ARCH GEN PSYCHIAT (ARCHIVES OF GENERAL PSYCHIATRY), J AFFECT DISORDERS (JOURNAL OF AFFECTIVE DISORDERS), and AM J PSYCHIAT (AMERICAN JOURNAL OF PSYCHIATRY), with co-citation counts of 20,499, 20,302, and 20,143, with co-citation rates of 2.09, 2.07, and 2.06%, respectively. The main research area of ARCH GEN PSYCHIAT is Psychiatry; the main research area of the journal J AFFECT DISORDERS is Neurosciences and Neurology, Psychiatry; AM J PSYCHIAT is the main research area of Psychiatry, and the three journals have “psychiatry” in common, making them the most frequently co-cited journals in the field of depression.
Table 2 . The top 15 co-cited journals.
Figure 3 shows the network relationship graph of the cited journals from 2004 to 2019. The figure takes g-index as the selection criteria, the scale factor k = 25 to include more nodes. Each node of the graph represents each journal, the node size represents the number of citation frequencies, the label size represents the size of the betweenness centrality of the journal in the network, and the links between journals represent the co-citation relationships. The journal co-citation map reflects the structure of the journals, indicating that there are links between journals and that the journals include similar research topics. These journals included research topics related to neuroscience, psychiatry, neurology, and psychology. The journal with betweenness centrality size in the top 1 was ARCH GEN PSYCHIAT, with betweenness centrality size of 0.07, and impact shadows of 14.48. ARCH GEN PSYCHIAT, has research themes of Psychiatry. In all, these journals in Figure 3 occupy an important position in the journal's co-citation network and have strong links with other journals.
Figure 3 . Prominent journals involved in depression. The betweenness centrality of a node in the network measures the importance of the position of the node in the network. Two types of nodes may have high betweenness centrality scores: (1) Nodes that are highly connected to other nodes, (2) Nodes are positioned between different groups of nodes. The lines represent the link between two different nodes.
Table 3 lists the 15 most popular categories in the field of depression research during the period 2004–2019. In general, the main disciplines involved are neuroscience, psychology, pharmacy, medicine, and health care, which are closely related to human life and health issues. Of these, psychiatry accounted for 20.78%, or about one-five, making it the most researched category. The study of depression focuses on neuroscience, reflecting the essential characteristics of depression as a category of mental illness and better reflecting the fact that depression is an important link in the human public health care. In addition, Table 3 shows that the category with the highest betweenness centrality is Neuroscience, followed by Public, Environment & Occupational Health, and then Pharmacology & Pharmacy, with betweenness centrality of 0.16, 0.13, and 0.11, respectively. It is found that the research categories of depression are also centered on disciplines such as neuroscience, public health and pharmacology, indicating that research on depression requires a high degree of integration of multidisciplinary knowledge and integration of information from various disciplines in order to have a more comprehensive and in-depth understanding of the depression.
Table 3 . The top 15 productive categories, 2004–2019.
Figure 4 shows the nine categories with the betweenness centrality in the category research network, with Neuroscience being the node with the highest betweenness centrality in this network, meaning that Neuroscience is most strongly linked to all research categories in the field of depression research. Depression is a debilitating psychiatric disorder with mood disorders. It is worth noting that the development of depression not only has psychological effects on humans, but also triggers many somatic symptoms that have a bad impact on their daily work and life, giving rise to the second major mediating central point of research with public health as its theme. The somatization symptoms of depression often manifest as abnormalities in the cardiovascular system, and many studies have looked at the pathology of the cardiovascular system in the hope of finding factors that influence the onset of depression, mechanisms that trigger it or new ways to treat it. Thus, depression involves not only the nervous system, but also interacts with the human cardiovascular system, for example, and the complexity of depression dictates that the study of depression is an in-depth study based on complex systems.
Figure 4 . Prominent categories involved in depression, 2004–2019. The betweenness centrality of a node in the network measures the importance of the position of the node in the network. Two types of nodes may have high betweenness centrality scores: (1) Nodes that are highly connected to other nodes, (2) Nodes are positioned between different groups of nodes. The lines represent the link between two different nodes.
The results of the analysis showed that there were many researchers working in the field of depression over the past 16 years, and 63 of the authors published at least 30 articles related to depression. Table 4 lists the 15 authors with the highest number of articles published. It includes the rank of the number of articles published, author, country, number of articles published in depression-related studies, total number of articles included in Web of Science, total number of citations, average number of citations, and H-index. According to the statistics, seven of the top 15 authors are from USA, three from the Netherlands, one from Canada, one from Australia, one from New Zealand, one from Italy, and one from Germany. From this, it can be seen that these productive authors are from developed countries, thus it can be inferred that developed countries have a better research environment, more advanced research technology and more abundant research funding. The evaluation indicators in the author co-occurrence network are frequency, betweenness centrality and time of first appearance. The higher the frequency, i.e., the higher the number of collaborative publications, the more collaboration, the higher the information dissemination rate, the three authors with the highest frequency in this author co-occurrence network are MAURIZIO FAVA, BRENDA W. J. H. PENNINX, MADHUKAR H. TRIVEDI; the higher the betweenness centrality, i.e., the closer the relationship with other authors, the more collaboration, the higher the information dissemination rate, the three authors with the highest betweenness centrality are the three authors with the highest betweenness centrality are MICHAEL E. THASE, A. JOHN RUSH; the time of first appearance, i.e., the longer the influence generated by the author's research, the higher the information dissemination rate; in addition, the impact factor and citations can also reflect the information dissemination efficiency of the authors.
Table 4 . The top 15 authors in network of co-authorship, 2004–2019.
The timezone view ( Figure 5 ) in the author co-occurrence network clearly shows the updates and interactions of author collaborations, for example. All nodes are positioned in a two-dimensional coordinate with the horizontal axis of time, and according to the time of first posting, the nodes are set in different time zones, and their positions are sequentially upward with the time axis, showing a left-to-right, bottom-up knowledge evolution diagram. The time period 2004–2019 is divided into 16 time zones, one for each year, and each circle in the figure represents an author, and the time zone in which the circle appears is the year when the author first published an article in the data set of this study. The closer the color, the warmer the color, the closer the time, the colder the color, the older the era, the thickness of an annual circle, and the number of articles within the corresponding time division is proportional, the dominant color can reflect the relative concentration of the emergence time, the nodes appear in the annual circle of the red annual circle, that is, on behalf of the hot spot, the frequency of being cited was or is still increasing sharply. Nodes with purple outer circles are nodes with high betweenness centrality. The time zone view demonstrates the growth of author collaboration in the field, and it can be found from the graph that the number of author collaborations increases over time, and the frequency of publications in the author collaboration network is high; observe that the thickness of the warm annual rings in the graph is much greater than the thickness of the cold annual rings, which represents the increase of collaboration in time; there are many authors in all time zones, which indicates that there are many research collaborations and achievements in the field, and the field is in a period of collaborative prosperity. The linkage relationship between the sub-time-periods can be seen by the linkage relationship between the time periods, and it can be found from the figure that there are many linkages in the field in all time periods, which indicates that the author collaboration in the field of depression research is strong.
Figure 5 . Timezone view of the author's co-existing network in depression, 2004–2019. The circle represents the author, the time zone in which the circle appears is the year in which the author first published in this study dataset, the radius of the circle represents the frequency of appearance, the color represents the different posting times, the lines represent the connections between authors, and the time zone diagram shows the evolution of author collaboration.
Table 5 lists the top 15 research institutions in network of co-authors' institutions. These include 10 American research institutions, two Netherlands research institutions, one UK research institution, one Canadian research institution and one Australian research institution, all of which, according to the statistics, are from developed countries. Of these influential research institutions, 66.7% are from USA. Figure 6 shows the collaborative network with these influential research institutions as nodes. Kings Coll London (0.2), Univ Michigan (0.17), Univ Toronto (0.15), Stanford Univ (0.14), Univ Penn (0.14), Univ Pittsburgh (0.14), Univ Melbourne (0.12), Virginia Commonwealth Univ (0.12), Columbia Univ (0.1), Duke Univ (0.1), Massachusetts Gen Hosp (0.1), Vrije Univ Amsterdam (0.1), with betweenness centrality >0.1. Kings Coll London has a central place in this collaborative network and is influential in the field of depression research. Table 6 lists the 15 institutions with the strong burst strength. The top 3 institutions are all from USA. Univ Copenhagen, Univ Illinois, Harvard Med Sch, Boston Univ, Univ Adelaide, Heidelberg Univ, Univ New South Wales, and Icahn Sch Med Mt Sinai have had strong burst strength in recent years. It suggests that these institutions may have made a greater contribution to the field of depression over the course of this year and more attention could be paid to their research.
Table 5 . The top 15 institutions in network of co-authors' institutions, 2004–2019.
Figure 6 . Prominent institutions involved in depression, 2004–2019. The betweenness centrality of a node in the network measures the importance of the position of the node in the network. Two types of nodes may have high betweenness centrality scores: (1) Nodes that are highly connected to other nodes, (2) Nodes are positioned between different groups of nodes. The lines represent the link between two different nodes.
Table 6 . The top 15 institutions with the strongest citation bursts, 2004–2019.
Summing up the above analysis, it can be seen that the research institutions in USA are at the center of the depression research field, are at the top of the world in terms of quantity and quality of research, and are showing continuous growth in vitality. Research institutions in USA, as pioneers among all research institutions, lead and drive the development of depression research and play an important role in cutting-edge research in the field of depression.
Table 7 lists the 16 articles that have been cited more than 1,000 times within the statistical range of this paper from 2004 to 2019. As can be seen from the table, the most cited article was written by Dowlati et al. from Canada and published in BIOLOGICAL PSYCHIATRY 2010, which was cited 2,556 times. In addition, 11 of these 16 highly cited articles were from the USA. Notably, two articles by Kroenke, K as first author appear in this list, ranked 7th and 11th, respectively. In addition, there are three articles from Canada, one article from Switzerland, and one article from the UK. And interestingly, all of these countries are developed countries. It can be reflected that developed countries have ample research experience and high quality of research in the field of depression research. On the other hand, it also reflects that depression is a key concern in developed countries. These highly cited articles provide useful information to many researchers and are of high academic and exploratory value.
Table 7 . The top 15 frequency cited articles, 2004–2019.
Keyword analysis.
The keyword analysis of depression yielded the 25 most frequent keywords in Table 8 and the keyword co-occurrence network in Figure 7 . Also, the data from this study were detected by burst, the 25 keywords with the strongest burst strength were obtained in Table 9 . These results bring out the popular and cutting-edge research directions in the field clearly.
Table 8 . Top 25 frequent keywords in the period of 2004–2019.
Figure 7 . Keyword co-occurrence network in depression, 2004–2019.
Table 9 . Top 25 keywords with strongest citation bursts in the period of 2004–2019.
The articles on depression during 2004–2019 were analyzed in 1-year time slices, and the top 25 keywords with the highest frequency of occurrence were selected from each slice to obtain the keyword network shown in Table 8 . The top 25 keywords with the highest frequencies were: symptom, disorder, major depression, prevalence, meta-analysis, anxiety, risk, scale, association, quality of life, health, risk factor, stress, validity, validation, mental health, women, double blind, brain, population, disease, impact, primary care, mood, and efficacy. High-frequency nodes respond to popular keywords and are an important basis for the field of depression research.
Figure 7 shows the co-occurrence network mapping of keywords regarding depression research. Each circle in the figure is a node representing a keyword, and the greater the betweenness centrality, the more critical the position of the node in the network. The top 10 keywords in terms of betweenness centrality are: symptom (0.6), major depression (0.28), prevalence (0.27), disorder (0.25), double blind (0.18), risk factor (0.12), stress (0.11), children (0.1), schizophrenia (0.1), and expression (0.1). Nodes with high betweenness centrality reflect that the keyword forms a co-occurrence relationship with multiple other keywords in the domain. A higher betweenness centrality indicates that it is more related to other keywords, and therefore, the node plays an important role in the study. Relatively speaking, these nodes represent the main research directions in the field of depression; they are also the key research directions in this period, and to a certain extent, represent the research hotspots in this period.
Burst detection was performed on the keywords, and the 25 keywords with the strongest strength were extracted, as shown in Table 9 . These keywords contain: fluoxetine, community, follow up, illness, psychiatric disorder, dementia, trial, placebo, disability, serotonin reuptake inhibitor, myocardial infarction, hospital anxiety, antidepressant treatment, late life depression, United States, epidemiology, major depression, model, severity, adolescent, people, prefrontal cortex, management, meta-analysis, and expression. The keywords that burst earlier include fluoxetine (2004), community (2004), follow up (2004), illness (2004), and psychiatric disorder (2004), are keywords that imply that researchers focused on themes early in the field of depression. As researchers continue to explore, the study of depression is changing day by day, and the keywords that have burst in recent years are people (2015), prefrontal cortex (2016), management (2016), meta-analysis (2017), and expression (2017). Reflecting the fact that depression research in recent years has mainly focused on human subjects, the focus has been on the characterization of populations with depression onset. The relationship between depression and the brain has aroused the curiosity of researchers, what exactly are the causes that trigger depression and what are the effects of depression for the manifestation of depression have caused a wide range of discussions in the research community, and the topics related to it have become the most popular studies and have been the focus of research in recent years. All of these research areas showed considerable growth, indicating that research into this area is gaining traction, suggesting that it is becoming a future research priority. The keywords with the strongest burst strength are fluoxetine (111.2), community (110.08), antidepressant treatment (94.28), severity (88.35), meta-analysis (86.42), people (85.33), and follow up (84.46). The rapid growth of research based on these keywords indicates that these topics are the most promising and interesting. The keywords that has been around the longest burst are follow up (2004–2013), model (2013–2019), hospital anxiety (2008–2013), severity (2014–2019), and psychiatric disorder (2004–2008), researchers have invested a lot of research time in these research directions, making many research results, and responding to the exploratory value and significance of research on these topics. At the same time, the longer duration of burst also proves that these research directions have research potential and important value.
Hotspots must mainly have the characteristics of high frequency, high betweenness centrality, strong burst, and time of emergence can be used as secondary evaluation indicators. The higher the number of occurrences, the higher the degree of popularity and attention. The higher betweenness centrality means the greater the influence and the higher the importance. Nodes with strong burst usually represent key shift nodes and need to be focused on. The time can be dynamically adjusted according to the target time horizon of the analysis. Thus, based on the results of statistical analysis, it is clear that the research hotspots in the field of depression can be divided into four main areas: etiology (external factors, internal factors), impact (quality of life, disease symptoms, co-morbid symptoms), treatment (interventions, drug development, care modalities), and assessment (population, size, symptoms, duration of disease, morbidity, mortality, effectiveness).
Risk factors for depression include a family history of depression, early life abuse and neglect, and female sexuality and recent life stressors. Physical illnesses also increase the risk of depression, particularly increasing the prevalence associated with metabolic (e.g., cardiovascular disease) and autoimmune disorders.
Research on the etiology of depression can be divided into internal and external factors. In recent years, researchers have increasingly focused on the impact of external factors on depression. Depression is influenced by environmental factors related to social issues, such as childhood experiences, social interactions, and lifestyles. Adverse childhood experiences are risk factors for depression and anxiety in adolescence ( 37 ) and are a common pathway to depression in adults ( 38 ). Poor interpersonal relationships with classmates, family, teachers, and friends increase the prevalence of depression in adolescents ( 39 ). Related studies assessed three important, specific indicators of the self-esteem domain: social confidence, academic ability, and appearance ( 40 ). The results suggest that these three dimensions of self-esteem are key risk factors for increased depressive symptoms in Chinese adolescents. The vulnerability model ( 41 ) suggests that low self-esteem is a causal risk factor for depression, and low self-esteem is thought to be one of the main causes of the onset and progression of depression, with individuals who exhibit low self-esteem being more likely to develop social anxiety and social withdrawal, and thus having a sense of isolation ( 42 ), which in turn leads to subsequent depression. Loneliness predicts depression in adolescents. Individuals with high levels of loneliness experience more stress and tension from psychological and physical sources in their daily lives, which, combined with insufficient care from society, can lead to depression ( 43 ). A mechanism of association exists between life events and mood disorders, with negative life events being directly associated with depressive symptoms ( 44 ). In a cross-sectional study conducted in Shanghai, the prevalence of depression was higher among people who worked longer hours, and daily lifestyle greatly influenced the prevalence of depression ( 45 ). A number of studies in recent years have presented a number of interesting ideas, and they suggest that depression is related to different environmental factors, such as temperature, sunlight hours, and air pollution. Environmental factors have been associated with suicidal behavior. Traffic noise is a variable that triggers depression and is associated with personality disorders such as depression ( 46 ). The harmful effects of air pollution on mental health, inhalation of air pollutants can trigger neuroinflammation and oxidative stress and induce dopaminergic neurotoxicity. A study showed that depression was associated with an increase in ambient fine particulate matter (PM2.5) ( 47 ).
Increased inflammation is a feature of many diseases and even systemic disorders, such as some autoimmune diseases [e.g., type 1 diabetes ( 48 ) or rheumatoid arthritis ( 49 )] and infectious diseases [e.g., hepatitis and sepsis ( 50 )], are associated with an inflammatory response and have been found to increase the risk of depression. A growing body of evidence supports a bidirectional association between depression and inflammatory processes, with stressors and pathogens leading to excessive or prolonged inflammatory responses when combined with predisposing factors (e.g., childhood adversity and modifying factors such as obesity). The resulting illnesses (e.g., pain, sleep disorders), depressive symptoms, and negative health (e.g., poor diet, sedentary lifestyle) may act as mediating pathways leading to inflammation and depression. In terms of mechanistic pathways, cytokines induce depression by affecting different mood-related processes. Elevated inflammatory signals can dysregulate the metabolism of neurotransmitters, damaging neurons, and thus altering neural activity in the brain. In addition cytokines can modulate depression by regulating hormone levels. Inflammation can have different effects on different populations depending on individual physiology, and even lower levels of inflammation may have a depressive effect on vulnerable individuals. This may be due to lower parasympathetic activity, poorer sensitivity to glucocorticoid inhibitory feedback, a greater response to social threat in the anterior oral cortex or amygdala and a smaller hippocampus. Indeed, these are all factors associated with major depression that can affect the sensitivity to the inhibitory consequences of inflammatory stimuli.
Depression triggers many somatization symptoms, which can manifest as insomnia, menopausal syndrome, cardiovascular problems, pain, and other somatic symptoms. There is a link between sleep deprivation and depression, with insomnia being a trigger and maintenance of depression, and more severe insomnia and chronic symptoms predicting more severe depression. Major depression is considered to be an independent risk factor for the development of coronary heart disease and a predictor of cardiovascular events ( 51 ). Patients with depression are extremely sensitive to pain and have increased pain perception ( 52 ) and is associated with an increased risk of suicide ( 53 , 54 ), and generally the symptoms of these pains are not relieved by medication.
Studies have shown that depression triggers an inflammatory response, promoting an increase in cytokines in response to stressors vs. pathogens. For example, mild depressive symptoms have been associated with an amplified and prolonged inflammatory response ( 55 , 56 ) following influenza vaccination in older adults and pregnant women. Among women who have recently given birth, those with a lifetime history of major depression have greater increases in both serum IL-6 and soluble IL-6 receptors after delivery than women without a history of depression ( 57 ). Pro-inflammatory agents, such as interferon-alpha (IFN-alpha), for specific somatization disorders [e.g., hepatitis C or malignant melanoma ( 58 , 59 )], although effective for somatic disorders, pro-inflammatory therapy often leads to psychiatric side effects. Up to 80% of patients treated with IFN-α have been reported to suffer from mild to moderate depressive symptoms.
Clinical trials have shown better antidepressant treatment with anti-inflammatory drugs compared to placebo, either as monotherapy ( 60 , 61 ) or as an add-on treatment ( 62 – 65 ) to antidepressants ( 66 , 67 ). However, findings like whether NSAIDs can be safely used in combination with antidepressants are controversial. Patients with depression often suffer from somatic co-morbidities, which must be included in the benefit/risk assessment. It is important to consider the type of medication, duration of treatment, and dose, and always balance the potential treatment effect with the risk of adverse events in individual patients. Depression, childhood adversity, stressors, and diet all affect the gut microbiota and promote gut permeability, another pathway that enhances the inflammatory response, and effective depression treatment may have profound effects on mood, inflammation, and health. Early in life gut flora colonization is associated with hypothalamic-pituitary-adrenal (HPA) axis activation and affects the enteric nervous system, which is associated with the risk of major depression, gut flora dysbiosis leads to the onset of TLR4-mediated inflammatory responses, and pro-inflammatory factors are closely associated with depression. Clinical studies have shown that in the gut flora of depressed patients, pro-inflammatory bacteria such as Enterobacteriaceae and Desulfovibrio are enriched, while short-chain fatty acid producing bacteria are reduced, and some of these bacterial taxa may transmit peripheral inflammation into the brain via the brain-gut axis ( 68 ). In addition, gut flora can affect the immune system by modulating neurotransmitters (5-hydroxytryptamine, gamma-aminobutyric acid, norepinephrine, etc.), which in turn can influence the development of depression ( 69 ). Therefore, antidepressant drugs targeting gut flora are a future research direction, and diet can have a significant impact on mood by regulating gut flora.
As the molecular basis of clinical depression remains unclear, and treatments and therapeutic effects are limited and associated with side effects, researchers have worked to discover new treatment modalities for depression. High-amplitude low-frequency musical impulse stimulation as an additional treatment modality seems to produce beneficial effects ( 70 ). Studies have found electroconvulsive therapy to be one of the most effective antidepressant treatment therapies ( 71 ). Physical exercise can promote molecular changes that lead to a shift from a chronic pro-inflammatory to an anti-inflammatory state in the peripheral and central nervous system ( 72 ). Aromatherapy is widely used in the treatment of central nervous system disorders ( 73 ). By activating the parasympathetic nervous system, qigong can be effective in reducing depression ( 74 ). The exploration of these new treatment modalities provides more reference options for the treatment of depression.
Large-scale assessments of depression have found that the probability of developing depression varies across populations. Depression affects some specific populations more significantly, for example: adolescents, mothers, and older adults. Depression is one of the disorders that predispose to adolescence, and depression is associated with an increased risk of suicide among college students ( 75 ). Many women develop depression after childbirth. Depression that develops after childbirth is one of the most common complications for women in the postpartum period ( 76 ). The health of children born to mothers who suffer from postpartum depression can also be adversely affected ( 77 ). Depression can cause many symptoms within the central nervous system, especially in the elderly population ( 78 ).
Furthermore, one of the most consistent findings of the association between inflammation and depression is the elevated levels of peripheral pro-inflammatory markers in depressed individuals, and peripheral pro-inflammatory marker levels can also be used as a basis for the assessment of depressed patients. Studies have shown that the following pro-inflammatory markers have been found to be at increased levels in depressed individuals: CRP ( 79 , 80 ), IL-6 ( 22 , 79 , 81 , 82 ), TNF–α, and interleukin-1 receptor antagonist (IL-1ra) ( 79 , 82 ), however, this association is not unidirectional and the subsequent development of depression also increases pro-inflammatory markers ( 82 , 83 ). These biomarkers are of great interest, and depressed patients with increased inflammatory markers may represent a relatively drug-resistant population.
The exploration and analysis of frontier areas of depression were based on the results of the analysis of the previous section on keywords. According to the evaluation index and analysis idea of this study, the frontier research topics need to have the following four characteristics: low to medium frequency, strong burst, high betweenness centrality, and the research direction in recent years. Therefore, combining the results of keyword analysis and these characteristics, it can be found that the frontier research on depression also becomes clear.
Exploration of biological mechanisms based on depression-associated neurological disorders and analysis of depression from a neurological perspective have always been the focus of research. Activation of neuroinflammatory pathways may contribute to the development of depression ( 84 ). A research model based on the microbial-gut-brain axis facilitates the neurobiology of depression ( 85 ). Some probiotics positively affect the central nervous system due to modulation of neuroinflammation and thus may be able to modulate depression ( 86 ). The combination of environmental issues and the neurobiological study of depression opens new research directions ( 46 ).
How to develop a model that meets the purpose of the study determines the outcome of the study and has become the direction that researchers have been exploring in recent years. Martínez et al. ( 87 ) developed a predictive model to assess factors that modify the treatment pathway for postpartum depression. Nie et al. ( 88 ) extended the work on predictive modeling of treatment-resistant depression to establish a predictive model for treatment-resistant depression. Rational modeling methods and behavioral testing facilitate a more comprehensive exploration of depression, with richer studies and more scientifically valid findings.
Current research on special groups and depression has received much attention. In a study of a group of children, 4% were found to suffer from depression ( 89 ). The diagnosis and treatment of mental health disorders is an important component of pediatric care. Second, some studies of populations with distinct characteristics have been based primarily on female populations. Maternal perinatal depression is also a common mental disorder with a prevalence of over 10% ( 90 ). In addition, geriatric depression is a chronic and specific disorder ( 91 ). Studies based on these populations highlight the characteristics of the disorder more directly than large-scale population explorations and are useful for conducting extended explorations from specific to generalized.
Depression often accompanies the onset and development of many other disorders, making the study of physical comorbidities associated with depression a new landing place for depression research. Depression is a complication of many neurological or psychopathological disorders. Depression is a common co-morbidity of glioblastoma multiforme ( 92 ). Depression is an important disorder associated with stroke ( 93 ). Chronic liver disease is associated with depression ( 94 ). The link between depressive and anxiety states and cancer has been well-documented ( 95 ). In conclusion, depression is associated with an increased risk of lung, oral, prostate, and skin cancers, an increased risk of cancer-specific death from lung, bladder, breast, colorectal, hematopoietic system, kidney, and prostate cancers, and an increased risk of all-cause mortality in lung cancer patients. The early detection and effective intervention of depression and its complications has public health and clinical implications.
Research based on the mechanisms of depression includes the study of disease pathogenesis, the study of drug action mechanisms, and the study of disease treatment mechanisms. Research on the pathogenesis of depression has focused more on the study of the hypothalamic-pituitary-adrenal axis. Social pressure can change the hypothalamic-pituitary-adrenal axis ( 96 ). Studies on the mechanism of action of drugs are mostly based on their effects on the central nervous system. The antidepressant effects of Tanshinone IIA are mediated by the ERK-CREB-BDNF pathway in the hippocampus of mice ( 97 ). Research on the mechanisms of depression treatment has also centered on the central nervous system. It has been shown that the vagus nerve can transmit signals to the brain that can lead to a reduction in depressive behavior ( 98 ).
In this study, based on the 2004–2019 time period, this wealth of data is effectively integrated through data analysis and processing to reproduce the research process in a particular field and to co-present global trends in homogenous fields while organizing past research.
Journals that have made outstanding contributions in this field include ARCH GEN PSYCHIAT, J AFFECT DISORDERS and AM J PSYCHIAT. PSYCHIATRY, NEUROSCIENCES & NEUROLOGY and CLINICAL NEUROLOGY are the three most popular categories. The three researchers with the highest number of articles were MAURIZIO FAVA (USA), BRENDA W. J. H. PENNINX (NETHERLANDS) and MADHUKAR H TRIVEDI (USA). Univ Pittsburgh (USA), Kings Coll London (UK) and Harvard Univ (USA) are three of the most productive and influential research institutions. A Meta-Analysis of Cytokines in Major Depression, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice and Deep brain stimulation for treatment-resistant depression are key articles. Through keyword analysis, a distribution network centered on depression was formed. Although there are good trends in the research on depression, there are still many directions to be explored in depth. Some recommendations regarding depression are as follows.
(1) The prevention of depression can be considered by focusing on treating external factors and guiding the individual.
Faced with the rising incidence of depression worldwide and the difficulty of treating depression, researchers can think more about how to prevent the occurrence of depression. Depressed moods are often the result of stress, not only social pressures on the individual, but also environmental pressures in the developmental process, which in turn have an unhealthy relationship with the body and increase the likelihood of depression. The correlation between external factors and depression is less well-studied, but the control of external factors may be more effective in the short term than in the long term, and may be guided by self-adjustment to avoid major depressive disorder.
(2) The measurement and evaluation of the degree of depression should be developed in the direction of precision.
In the course of research, it has been found that the Depression Rating Scale is mostly used for the detection and evaluation of depression. This kind of assessment is more objective, but it still lacks accuracy, and the research on measurement techniques and methods is less, which is still at a low stage. Patients with depression usually have a variety of causes, conditions, and duration of illness that determine the degree of depression. Therefore, whether these scales can truly accurately measure depression in depressed patients needs further consideration. Accurate measurement is an important basis for evidence-based treatment of depression, and thus how to achieve accurate measurement of depression is a research direction that researchers can move toward.
Therefore, there is an urgent need for further research to address these issues.
A systematic analysis of research in the field of depression in this study concludes that the distribution of countries, journals, categories, authors, institutions, and citations may help researchers and research institutions to establish closer collaboration, develop appropriate publication plans, grasp research hotspots, identify valuable research ideas, understand current emerging research, and determine research directions. In addition, there are still some limitations that can be overcome in future work. First, due to the lack of author and address information in older published articles, it may not be possible to accurately calculate their collaboration; second, although the data scope of this paper is limited to the Web of Science, it can adequately meet our objectives.
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.
HW conceived and designed the analysis, collected the data, performed the analysis, and wrote the paper. XT, XW, and YW conceived and designed the analysis. All authors contributed to the article and approved the submitted version.
This work was supported by the National Natural Science Foundation of China under Grant No. 81973495.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
1. Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci. (2009) 10:434–45. doi: 10.1038/nrn2639
PubMed Abstract | CrossRef Full Text | Google Scholar
2. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. (2013) 34:119–38. doi: 10.1146/annurev-publhealth-031912-114409
3. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. (2007) 370:851–8. doi: 10.1016/S0140-6736(07)61415-9
4. Peter Heutink MR. The genetics of MDD – a review of challenges and opportunities. J Depress Anxiety. (2014) 3:150. doi: 10.4172/2167-1044.1000150
CrossRef Full Text | Google Scholar
5. Melchior M, Caspi A, Milne BJ, Danese A, Poulton R, Moffitt TE. Work stress precipitates depression and anxiety in young, working women and men. Psychol Med. (2007) 37:1119–29. doi: 10.1017/S0033291707000414
6. Fusar-Poli P, Solmi M, Brondino N, Davies C, Chae C, Politi P, et al. Transdiagnostic psychiatry: a systematic review. World Psychiatry. (2019) 18:192–207. doi: 10.1002/wps.20631
7. Hammarström A, Lehti A, Danielsson U, Bengs C, Johansson EE. Gender-related explanatory models of depression: a critical evaluation of medical articles. Public Health. (2009) 123:689–93. doi: 10.1016/j.puhe.2009.09.010
8. Tran BX, Ho RCM, Ho CSH, Latkin CA, Phan HT, Ha GH, et al. Depression among patients with HIV/AIDS: research development and effective interventions (gapresearch). Int J Environ Res Public Health. (2019) 16:1772. doi: 10.3390/ijerph16101772
9. Wang XQ, Peng MS, Weng LM, Zheng YL, Zhang ZJ, Chen PJ. Bibliometric study of the comorbidity of pain and depression research. Neural Plast. (2019) 2019:1657498. doi: 10.1155/2019/1657498
10. Shi S, Gao Y, Sun Y, Liu M, Shao L, Zhang J, et al. The top-100 cited articles on biomarkers in the depression field: a bibliometric analysis. Psychol Heal Med. (2020) 26:533–42. doi: 10.1080/13548506.2020.1752924
11. Dongping G, Ami D, Ranran D, Yuan Y, Xiaobei S, Xiaoyao W, et al. A study of the relationship between depression and intestinal flora based on bibliometrics. China Med Her. (2017) 14:173–6.
12. Chunping A, Haiyan W, Nina H, Pinghui H. Bibiometrics analysis of acupuncture for treating depression based on GoPubMed. J Clin Acupunct Moxibustion. (2017) 33:54–7.
13. Yi Y, Xiaoli W. Bibiometrics analysis of acupuncture for treating depression based on GoPubMed. Mod Chinese Med. (2012) 14:35–8. doi: 10.13313/j.issn.1673-4890.2012.09.013
CrossRef Full Text
14. Zhou X, Yan F. Analysis on scientific and technological achievements in the field of depression during 1999-2017. J Prev Med Inf. (2019) 35:777–82.
15. Guaijuan W. Bibliometric analysis of literatures of psoriasis and depression based on GoPubmed. J Dermatol Venereol. (2017) 39:391–4.
16. Yunzhi C, Jie G, Yihui C, Chen G, Chen W, Wang H, et al. A Bibliometric analysis on research of vitamin D deficiency and depression caused. J Guiyang Coll Tradit Chinese Med. (2016) 38:32–5.
17. Shaoni L, Shumin R, Chunhui Z, Yongxiao T, Qizheng Z. Bibliometric analysis of depression-related genes. Chinese J Med Libr Inf Sci. (2009) 18:75–8.
18. Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol. (2014) 57:359–77. doi: 10.1002/asi.20317
19. Elgendi M. Scientists need data visualization training. Nat Biotechnol. (2017) 35:990–1. doi: 10.1038/nbt.3986
20. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates (2017).
Google Scholar
21. World Health Organization. Human Development Report 2020 (2020).
22. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. (2010) 67:446–57. doi: 10.1016/j.biopsych.2009.09.033
23. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR * D: implications for clinical practice. Am J Psychiatry. (2006) 163:28–40. doi: 10.1176/appi.ajp.163.1.28
24. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. (2005) 45:651–60. doi: 10.1016/j.neuron.2005.02.014
25. Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry . (2006) 67:793–802. doi: 10.1001/archgenpsychiatry.2010.90
26. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. (2008) 455:894–902. doi: 10.1038/nature07455
27. Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. (2009) 114:163–73. doi: 10.1016/j.jad.2008.06.026
28. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci. (2005) 8:828–34. doi: 10.1038/nn1463
29. Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, et al. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry. (2007) 62:429–37. doi: 10.1016/j.biopsych.2006.09.020
30. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. (2006) 9:519–25. doi: 10.1038/nn1659
31. Kroenke K, Spitzer RL, Williams JBW, Löwe B. An Ultra-Brief Screening Scale for anxiety and depression: the PHQ−4. Psychosomatics. (2009) 50:613–21. doi: 10.1016/s0033-3182(09)70864-3
32. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. J Pediatr. (2005) 146:145. doi: 10.1016/j.jpeds.2004.10.032
33. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder. Arch Gen Psychiatry. (2005) 62:1097. doi: 10.1001/archpsyc.62.10.1097
34. Gotlib IH, Joormann J. Cognition and depression: current status and future directions. Annu Rev Clin Psychol. (2010) 6:285–312. doi: 10.1146/annurev.clinpsy.121208.131305
35. Robertson E, Grace S, Wallington T, Stewart DE. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry. (2004) 26:289–95. doi: 10.1016/j.genhosppsych.2004.02.006
36. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. (2011) 12:160–74. doi: 10.1016/S1470-2045(11)70002-X
37. Wang D, Jiang Q, Yang Z, Choi JK. The longitudinal influences of adverse childhood experiences and positive childhood experiences at family, school, and neighborhood on adolescent depression and anxiety. J Affect Disord. (2021) 292:542–51. doi: 10.1016/j.jad.2021.05.108
38. LeMasters K, Bates LM, Chung EO, Gallis JA, Hagaman A, Scherer E, et al. Adverse childhood experiences and depression among women in rural Pakistan. BMC Public Health. (2021) 21:400. doi: 10.1186/s12889-021-10409-4
39. Zhao Y, Zhao Y, Lee YT, Chen L. Cumulative interpersonal relationship risk and resilience models for bullying victimization and depression in adolescents. Pers Individ Dif. (2020) 155:109706. doi: 10.1016/j.paid.2019.109706
40. Zhou J, Li X, Tian L, Huebner ES. Longitudinal association between low self-esteem and depression in early adolescents: the role of rejection sensitivity and loneliness. Psychol Psychother Theor Res Pract. (2020) 93:54–71. doi: 10.1111/papt.12207
41. Butler AC, Hokanson JE, Flynn HA. A comparison of self-esteem lability and low trait self-esteem as vulnerability factors for depression. J Pers Soc Psychol. (1994) 66:166–77. doi: 10.1037/0022-3514.66.1.166
42. Watson J, Nesdale D. Rejection sensitivity, social withdrawal, and loneliness in young adults. J Appl Soc Psychol. (2012) 42:1984–2005. doi: 10.1111/j.1559-1816.2012.00927.x
43. Teo AR, Marsh HE, Forsberg CW, Nicolaidis C, Chen JI, Newsom J, et al. Loneliness is closely associated with depression outcomes and suicidal ideation among military veterans in primary care. J Affect Disord. (2018) 230:42–9. doi: 10.1016/j.jad.2018.01.003
44. Sarubin N, Goerigk S, Padberg F, Übleis A, Jobst A, Erfurt L, et al. Self-esteem fully mediates positive life events and depressive symptoms in a sample of 173 patients with affective disorders. Psychol Psychother Theor Res Pract. (2020) 93:21–35. doi: 10.1111/papt.12205
45. Li Z, Dai J, Wu N, Jia Y, Gao J, Fu H. Effect of long working hours on depression and mental well-being among employees in Shanghai: the role of having leisure hobbies. Int J Environ Res Public Health. (2019) 16:4980. doi: 10.3390/ijerph16244980
46. Díaz J, López-Bueno JA, López-Ossorio JJ, Gónzález JL, Sánchez F, Linares C. Short-term effects of traffic noise on suicides and emergency hospital admissions due to anxiety and depression in Madrid (Spain). Sci Total Environ. (2020) 710:136315. doi: 10.1016/j.scitotenv.2019.136315
47. Fan SJ, Heinrich J, Bloom MS, Zhao TY, Shi TX, Feng WR, et al. Ambient air pollution and depression: a systematic review with meta-analysis up to 2019. Sci Total Environ . (2020) 701:134721. doi: 10.1016/j.scitotenv.2019.134721
48. Korczak DJ, Pereira S, Koulajian K, Matejcek A, Giacca A. Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link. Diabetologia. (2011) 54:2483–93. doi: 10.1007/s00125-011-2240-3
49. Dickens C, McGowan L, Clark-Carter D, Creed F. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med. (2002) 64:52–60. doi: 10.1097/00006842-200201000-00008
50. Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, et al. Autoimmune diseases and severe infections as risk factors for mood disorders a nationwide study. JAMA Psychiatry. (2013) 70:812–20. doi: 10.1001/jamapsychiatry.2013.1111
51. Charlson FJ, Stapelberg NJC, Baxter AJ, Whiteford HA. Should global burden of disease estimates include depression as a risk factor for coronary heart disease? BMC Med. (2011) 9:47. doi: 10.1186/1741-7015-9-47
52. Velly AM, Mohit S. Epidemiology of pain and relation to psychiatric disorders. Prog Neuro Psychopharmacol Biol Psychiatry. (2018) 87:159–67. doi: 10.1016/j.pnpbp.2017.05.012
53. Razali SM, Khalib AQ. Pain symptoms in Malay patients with major depression. Asian J Psychiatr. (2012) 5:297–302. doi: 10.1016/j.ajp.2012.02.015
54. Bahk WM, Park S, Jon DI, Yoon BH, Min KJ, Hong JP. Relationship between painful physical symptoms and severity of depressive symptomatology and suicidality. Psychiatry Res. (2011) 189:357–61. doi: 10.1016/j.psychres.2011.01.009
55. Glaser R, Robles TF, Sheridan J, Malarkey WB, Kiecolt-Glaser JK. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry. (2003) 60:1009–14. doi: 10.1001/archpsyc.60.10.1009
56. Christian LM, Franco A, Iams JD, Sheridan J, Glaser R. Depressive symptoms predict exaggerated inflammatory responses to an in vivo immune challenge among pregnant women. Brain Behav Immun. (2010) 24:49–53. doi: 10.1016/j.bbi.2009.05.055
57. Maes M, Ombelet W, De Jongh R, Kenis G, Bosmans E. The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system. J Affect Disord. (2001) 63:85–92. doi: 10.1016/S0165-0327(00)00156-7
58. Friebe A, Horn M, Schmidt F, Janssen G, Schmid-Wendtner MH, Volkenandt M, et al. Dose-dependent development of depressive symptoms during adjuvant interferon-α treatment of patients with malignant melanoma. Psychosomatics . (2010) 51:466–73. doi: 10.1016/s0033-3182(10)70738-6
59. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. (2008) 372:117–26. doi: 10.1016/S0140-6736(08)61033-8
60. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. (2006) 367:29–35. doi: 10.1016/S0140-6736(05)67763-X
61. Iyengar RL, Gandhi S, Aneja A, Thorpe K, Razzouk L, Greenberg J, et al. NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med . (2013) 126:1017.e11–8. doi: 10.1016/j.amjmed.2013.02.037
62. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. (2006) 11:680–4. doi: 10.1038/sj.mp.4001805
63. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. (2009) 26:607–11. doi: 10.1002/da.20589
64. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. J Affect Disord. (2012) 141:308–14. doi: 10.1016/j.jad.2012.03.033
65. Majd M, Hashemian F, Hosseinib SM, Shariatpanahi MV, Sharifid A. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in treatment of drug-naive depressed women: a pilot study. Iran J Pharm Res. (2015) 14:891–9. doi: 10.22037/ijpr.2015.1637
66. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci USA. (2011) 108:9262–7. doi: 10.1073/pnas.1104836108
67. Uher R, E TK, Tracy D, Wolfgang M, Ole M, Joanna H, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. (2014) 171:1278–86. doi: 10.1176/appi.ajp.2014.14010094
68. Simpson CA, Diaz-Arteche C, Eliby D, Schwartz OS, Simmons JG, Cowan CSM. The gut microbiota in anxiety and depression – a systematic review. Clin Psychol Rev. (2021) 83:101943. doi: 10.1016/j.cpr.2020.101943
69. Yang Z, Li J, Gui X, Shi X, Bao Z, Han H, et al. Updated review of research on the gut microbiota and their relation to depression in animals and human beings. Mol Psychiatry. (2020) 25:2759–72. doi: 10.1038/s41380-020-0729-1
70. Sigurdardóttir GA, Nielsen PM, Rønager J, Wang AG. A pilot study on high amplitude low frequency–music impulse stimulation as an add-on treatment for depression. Brain Behav. (2019) 9:e01399. doi: 10.1002/brb3.1399
71. Maffioletti E, Gennarelli M, Gainelli G, Bocchio-Chiavetto L, Bortolomasi M, Minelli A. BDNF genotype and baseline serum levels in relation to electroconvulsive therapy effectiveness in treatment-resistant depressed patients. J ECT. (2019) 35:189–94. doi: 10.1097/YCT.0000000000000583
72. Ignácio ZM, da Silva RS, Plissari ME, Quevedo J, Réus GZ. Physical exercise and neuroinflammation in major depressive disorder. Mol Neurobiol. (2019) 56:8323–35. doi: 10.1007/s12035-019-01670-1
73. Lu Z, Zhang T, Wang X, Wang J, Shen J, Xiao Z, et al. Zwitterionic polymer-based nanoparticles encapsulated with linalool for regulating central nervous system. ACS Biomater Sci Eng. (2020) 6:442–9. doi: 10.1021/acsbiomaterials.9b01451
74. Koo JW, Chaudhury D, Han MH, Nestler EJ. Role of mesolimbic brain-derived neurotrophic factor in depression. Biol Psychiatry. (2019) 86:738–48. doi: 10.1016/j.biopsych.2019.05.020
75. Seppälä EM, Bradley C, Moeller J, Harouni L, Nandamudi D, Brackett MA. Promoting mental health and psychological thriving in university students: a randomized controlled trial of three well-being interventions. Front Psychiatry. (2020) 11:590. doi: 10.3389/fpsyt.2020.00590
76. Weissman M, Olfson M. Depression in women: implications for health care research. Science. (1995) 269:799–801. doi: 10.2105/AJPH.2020.305798
77. Savory K, Garay SM, Sumption LA, Kelleher JS, Daughters K, Janssen AB, et al. Prenatal symptoms of anxiety and depression associated with sex differences in both maternal perceptions of one year old infant temperament and researcher observed infant characteristics. J Affect Disord. (2020) 264:383–92. doi: 10.1016/j.jad.2019.11.057
78. Eraydin IE, Mueller C, Corbett A, Ballard C, Brooker H, Wesnes K, et al. Investigating the relationship between age of onset of depressive disorder and cognitive function. Int J Geriatr Psychiatry. (2019) 34:38–46. doi: 10.1002/gps.4979
79. Howren MB, Lamkin DM, Suls J. Associations of depression with c-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. (2009) 71:171–86. doi: 10.1097/PSY.0b013e3181907c1b
80. Wium-Andersen MK, Ørsted DD, Nielsen SF, Nordestgaard BG. Elevated C-reactive protein levels, psychological distress, and depression in 73131 individuals. JAMA Psychiatry. (2013) 70:176–84. doi: 10.1001/2013.jamapsychiatry.102
81. Liu Y, Ho RCM, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. (2012) 139:230–9. doi: 10.1016/j.jad.2011.08.003
82. Dahl J, Ormstad H, Aass HCD, Malt UF, Bendz LT, Sandvik L, et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology. (2014) 45:77–86. doi: 10.1016/j.psyneuen.2014.03.019
83. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life a population-based longitudinal study. JAMA Psychiatry. (2014) 71:1121–8. doi: 10.1001/jamapsychiatry.2014.1332
84. Zhang Z, xuan, Li E, Yan J, ping, Fu W, Shen P, Tian SW, et al. Apelin attenuates depressive-like behavior and neuroinflammation in rats co-treated with chronic stress and lipopolysaccharide. Neuropeptides. (2019) 77:101959. doi: 10.1016/j.npep.2019.101959
85. Tian P, O'Riordan KJ, Lee Y, kun, Wang G, Zhao J, Zhang H, et al. Towards a psychobiotic therapy for depression: Bifidobacterium breve CCFM1025 reverses chronic stress-induced depressive symptoms and gut microbial abnormalities in mice. Neurobiol Stress. (2020) 12:100216. doi: 10.1016/j.ynstr.2020.100216
86. Paiva IHR, Duarte-Silva E, Peixoto CA. The role of prebiotics in cognition, anxiety, and depression. Eur Neuropsychopharmacol. (2020) 34:1–18. doi: 10.1016/j.euroneuro.2020.03.006
87. Martínez P, Vöhringer PA, Rojas G. Barreiras de acesso a tratamento para mães com depressão pós-parto em centros de atenção primária: Um modelo preditivo. Rev Lat Am Enfermagem. (2016) 24:e2675. doi: 10.1590/1518-8345.0982.2675
88. Nie Z, Vairavan S, Narayan VA, Ye J, Li QS. Predictive modeling of treatment resistant depression using data from STARD and an independent clinical study. PLoS ONE. (2018) 13:e0197268. doi: 10.1371/journal.pone.0197268
89. Elmore AL, Crouch E. The Association of adverse childhood experiences with anxiety and depression for children and youth, 8 to 17 years of age. Acad Pediatr. (2020) 20:600–8. doi: 10.1016/j.acap.2020.02.012
90. Cheng B, Wang X, Zhou Y, Li J, Zhao Y, Xia S, et al. Regional cerebral activity abnormality in pregnant women with antenatal depression. J Affect Disord. (2020) 274:381–8. doi: 10.1016/j.jad.2020.05.107
91. Senel B, Özel-Kizil ET, Sorgun MH, Tezcan-Aydemir S, Kirici S. Transcranial sonography imaging of brainstem raphe, substantia nigra and cerebral ventricles in patients with geriatric depression. Int J Geriatr Psychiatry. (2020) 35:702–11. doi: 10.1002/gps.5287
PubMed Abstract | CrossRef Full Text
92. Mugge L, Mansour TR, Crippen M, Alam Y, Schroeder J. Depression and glioblastoma, complicated concomitant diseases: a systemic review of published literature. Neurosurg Rev. (2020) 43:497–511. doi: 10.1007/s10143-018-1017-2
93. Allida S, Kl C, Cf H, Lang H, House A, Ml H. Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression after stroke. Cochrane Database Syst Rev. (2020) 1:CD003437. doi: 10.1002/14651858.CD003437.pub4
94. Lee K, Otgonsuren M, Younoszai Z, Mir HM, Younossi ZM. Association of chronic liver disease with depression: a population-based study. Psychosomatics. (2013) 54:52–9. doi: 10.1016/j.psym.2012.09.005
95. Wang YH, Li JQ, Shi JF, Que JY, Liu JJ, Lappin JM, et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. (2020) 25:1487–99. doi: 10.1038/s41380-019-0595-x
96. Colaianna M, Schiavone S, Zotti M, Tucci P, Morgese MG, Bäckdahl L, et al. Neuroendocrine profile in a rat model of psychosocial stress: relation to oxidative stress. Antioxida Redox Signal. (2013) 18:1385–99. doi: 10.1089/ars.2012.4569
97. Lu J, Zhou H, Meng D, Zhang J, Pan K, Wan B, et al. Tanshinone IIA Improves depression-like behavior in mice by activating the ERK-CREB-BDNF signaling pathway. Neuroscience. (2020) 430:1–11. doi: 10.1016/j.neuroscience.2020.01.026
98. McVey Neufeld KA, Bienenstock J, Bharwani A, Champagne-Jorgensen K, Mao YK, West C, et al. Oral selective serotonin reuptake inhibitors activate vagus nerve dependent gut-brain signalling. Sci Rep. (2019) 9:14290. doi: 10.1038/s41598-019-50807-8
Keywords: depression, major depressive disorder, bibliometrics, visual analysis, knowledge graphs, CiteSpace
Citation: Wang H, Tian X, Wang X and Wang Y (2021) Evolution and Emerging Trends in Depression Research From 2004 to 2019: A Literature Visualization Analysis. Front. Psychiatry 12:705749. doi: 10.3389/fpsyt.2021.705749
Received: 06 May 2021; Accepted: 05 October 2021; Published: 29 October 2021.
Reviewed by:
Copyright © 2021 Wang, Tian, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yun Wang, wangyun@bucm.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Welcome to our list of the Great Depression topics! Here, you will find writing ideas about the causes and effects of the Great Depression. You can also pick plenty of related issues to debate.
š best great depression topic ideas & essay examples, š” good great depression essay topics, ā interesting topics to write about great depression, ā great depression essay questions, š great depression research topics.
IvyPanda. (2024, February 27). 124 Great Depression Topics to Write about & Examples. https://ivypanda.com/essays/topic/great-depression-essay-examples/
"124 Great Depression Topics to Write about & Examples." IvyPanda , 27 Feb. 2024, ivypanda.com/essays/topic/great-depression-essay-examples/.
IvyPanda . (2024) '124 Great Depression Topics to Write about & Examples'. 27 February.
IvyPanda . 2024. "124 Great Depression Topics to Write about & Examples." February 27, 2024. https://ivypanda.com/essays/topic/great-depression-essay-examples/.
1. IvyPanda . "124 Great Depression Topics to Write about & Examples." February 27, 2024. https://ivypanda.com/essays/topic/great-depression-essay-examples/.
Bibliography
IvyPanda . "124 Great Depression Topics to Write about & Examples." February 27, 2024. https://ivypanda.com/essays/topic/great-depression-essay-examples/.
Citing journal articles.
APA: Citing Journal Articles from Lawrence W. Tyree Library on Vimeo . View a transcript here.
In this tutorial, you will learn the basics for citing journal articles with and without a DOI and how to cite open access journal articles.
Every APA reference needs four parts: author, date, title, and source . As you go through these examples, you will learn how to identify these four parts and how to place and format them into a proper APA reference.
For the first example, you will learn how to cite a journal article with a DOI. Often, you will find journal articles online using the library's databases or other online resources.
The first step is to identify the author of the article. The author of this article is Brittanie Atteberry-Ash,
To list an author, write the last name , a comma , and the first and middle initials .
Example: Atteberry-Ash.
Next, identify when this article was published. For journal articles, you typically only need the year . In this case, this article was published in 2022. You can usually find the date at the top of the article, the cover of the journal, or, for online articles, the article's record.
List the date after the author(s), in parentheses , followed by a period .
Example: Atteberry-Ash, B. (2022).
Now, identify the title of the article . The title will usually be at the very top of the article, in a larger size font.
List the title of the article after the date. Make sure you only capitalize the first word of the title , the first word of the subtitle , which comes after a colon, and any proper nouns . End with a period. In this title, only the words Social and A are capitalized.
Example: Atteberry-Ash, B. (2022). Social work and social justice: A conceptual review.
For the last component, you need the source . For an article, this is the title of the journal, volume, issue , which is sometimes called number , and page numbers of the article. Usually this information can be found on the cover of the journal, on the table of contents, or at the top of the article. For the page numbers, you should look at the first and last pages of the article. For online articles, this information is usually found in the article's record.
Type the journal title , in italics , capitalizing all major words, a comma, the volume , also in italics , the number or issue in parentheses, a comma, and then the page numbers of the article.
Example: Atteberry-Ash, B. (2022). Social work and social justice: A conceptual review. Social Work, 68 (1), 38-46.
The last element of the source is the DOI , which stands for Digital Object Identifier. A DOI can be found in the article’s record or on the first page of the article.
Type the DOI , using the prefix https://doi.org/ . There is no period after the DOI.
Example: Atteberry-Ash, B. (2022). Social work and social justice: A conceptual review. Social Work, 68 (1), 38-46. https://doi.org/10.1093/sw/swac042
If you refer to a work in your paper, either by directly quoting, paraphrasing, or by referring to main ideas, you will need to include an in-text parenthetical citation. There are a number of ways to do this. In this example, a signal phrase is used to introduce a direct quote. The author's name is given in the text, and the publication date and page number(s) are enclosed in parentheses at the beginning and end of the sentence.
Example: Atteberry-Ash (2022) notes "social workers are called on to practice socially just values and to address the consequences of oppression, specifically lost opportunity, social disenfranchisement, and isolation" (p. 38).
In this example, most of the components needed for the reference can be found in the article’s record. This article, however, has multiple authors and does not have a DOI listed in its record or in the article itself.
Format all the citation components of this journal article like the first example. For multiple authors, list the authors in the order they are listed in the article. Use a comma to separate each author and an ampersand (&) should be placed before the last author’s name. This applies for articles with up to twenty authors. Since there is no DOI listed for this article, simply omit that element. The reference will conclude after the page numbers.
Example: Penprase, B., Mileto, L., Bittinger, A., Hranchook, A. M., Atchley, J. A., Bergakker, S., Eimers, T., & Franson, H. (2012). The use of high-fidelity simulation in the admissions process: One nurse anesthesia program’s experience. AANA Journal, 80 (1), 43–48.
If you refer to a work in your paper that has three or more authors, the in-text citation will include the first author's name only, followed by et al. which means "and all the rest."
Example: Penprase et al. (2012) states that "Admission into nurse anesthesia programs is known to be a competitive process among a diverse pool of candidates" (p. 43).
This article was found in PLOS One which is an open access journal. Open access journal articles are articles with the full text freely available online and do not require logging in.
You will need all of the same information from the previous examples to cite an open access article. In this example, most of this information can be found at the top of the article.
In this example, the article's volume, issue, and the article number are found in the citation provided by the journal. Article numbers are used in place of page numbers in some online journals.
The format for open access journals is the same as the other examples. In this example, an article number is used in place of the page numbers. After the issue number, type Article and then the article number. If an open access journal does not provide a DOI, you may provide the URL of the article instead. Only include the URL if it directly brings you to the full text of the article without logging in.
Example: Francis, H. M., Stevenson, R. J., Chambers, J. R., Gupta, D., Newey, B., & Lim, C. K. (2019). A brief diet intervention can reduce symptoms of depression in young adults – A randomised controlled trial. PLOS ONE, 14 (1), Article e0222768. https://doi.org/10.1371/journal.pone.0222768
IMAGES
VIDEO
COMMENTS
The possible causes of depression are many and not yet well understood. However, it most likely results from an interplay of genetic vulnerability and environmental factors. Your depression research paper could explore one or more of these causes and reference the latest research on the topic. For instance, how does an imbalance in brain ...
StudyCorgi has prepared a list of titles for depression essays and research questions that you can use for your presentation, persuasive paper, and other writing assignments. Read on to find your perfect research title about depression! Table of Contents. š TOP 7 Depression Title Ideas.
This review may be used as an evidence base by those in public health, clinical practice, and research. This paper discusses key areas in depression research; however, an exhaustive discussion of all the risk factors and determinants linked to depression and their mechanisms is not possible in one journal articleāwhich, by its very nature, a ...
Table of Contents. Depression is a disorder characterized by prolonged periods of sadness and loss of interest in life. The symptoms include irritability, insomnia, anxiety, and trouble concentrating. This disorder can produce physical problems, self-esteem issues, and general stress in a person's life. Difficult life events and trauma are ...
To help you get started, here are 112 depression essay topic ideas and examples: The impact of depression on academic performance. Depression: A silent epidemic. The correlation between depression and substance abuse. The role of genetics in depression. The effects of childhood trauma on adult depression.
Sadness is a common human emotion, but depression encompasses more than just sadness. As reported by the National Institute of Mental Health, around 21 million adults in the United States, roughly 8.4% of the total adult population, faced at least one significant episode of depression in 2020.
Depression is a common psychiatric disorder and a major contributor to the global burden of diseases. According to the World Health Organization, depression is the second-leading cause of disability in the world and is projected to rank first by 2030 [1]. Depression is also associated with high rates of suicidal behavior and mortality [2].
Analysis of Published Papers. In the past decade, the total number of papers on depression published worldwide has increased year by year as shown in Fig. Fig.1A. 1 A. Searching the Web of Science database, we found a total of 43,863 papers published in the field of depression from 2009 to 2019 (search strategy: TI = (depression$) or ts = ("major depressive disorder$")) and py = (2009-2019 ...
As part of the Improving Mood with Psychoanalytic and Cognitive Therapies - My Experience (IMPACT-ME) study (Midgley, Ansaldo, & Target, 2014), the research team created a film together with the YP and parents on the experience of depression and therapy that is freely available and may be used for educational purposes ("Facing Shadows ...
All of our topics are interesting, so you won't get bored while writing your paper. You can use them for free - simply choose one and start writing! Table of contents hide. 1 Depression research topics for sociology papers. 2 Depression topics for history papers. 3 Depression research paper topics for health care papers.
Depression is a global health concern, with various treatments available. In this study, participants (n = 430) were self-selected or medically referred to a residential lifestyle program at the Black Hills Health & Education Center (BHHEC), with a mean stay of 19 days.
Here are a few ideas to get you started. The impact of genetics on the susceptibility to depression. Efficacy of antidepressants vs. cognitive behavioural therapy. The role of gut microbiota in mood regulation. Cultural variations in the experience and diagnosis of bipolar disorder.
In all, 16 studies reported the prevalence of depression among a total of 23,469 Ph.D. students (Fig. 2; range, 10-47%).Of these, the most widely used depression scales were the PHQ-9 (9 studies ...
Depressive disorders are common, costly, have a strong effect on quality of life, and are associated with considerable morbidity and mortality. Effective treatments are available: antidepressant medication and talking therapies are included in most guidelines as first-line treatments. These treatments have changed the lives of countless patients worldwide for the better and will continue to do ...
Data Sources. The data in this paper comes from the Web of Science (WoS) core collection. The time years were selected as 2004-2019. First, the literature was retrieved after entering "depression" using the title search method.
Research Open Access 06 Sept 2024 Scientific Reports Volume: 14, P: 20870 Astrocytic RARĪ³ mediates hippocampal astrocytosis and neurogenesis deficits in chronic retinoic acid-induced depression
Schizophrenia and bipolar disorder are examples of such confusion. Adult Depression and Anxiety as a Complex Problem. Psychology essay sample: The presence of a physical disability is a major factor in developing a mental health condition due to the increase in dissatisfaction and the presence of multiple irritants.
The number of trials that meet inclusion has increased considerably over time. In Fig. 1, we have given a cumulative overview of the included trials over the years and separately across different regions.As can be seen, up to the mid 1990s almost all research was done in North America, since then a growing number of trials has been done in Europe (including the UK) and since 2005 research in ...
Abstract. Major depression is a mood disorder characterized by a sense of inadequacy, despondency, decreased activity, pessimism, anhedonia and sadness where these symptoms severely disrupt and ...
METHODS. This study was done with an approved Arizona State University Institutional Review Board protocol #7247. In Fall 2018, we surveyed undergraduate researchers majoring in the life sciences across 25 research-intensive (R1) public institutions across the United States (specific details about the recruitment of the students who completed the survey can be found in Cooper et al.).
The research is done on both gender, male and female. 29 students are female and. male students are 112. This portion of research is to check whether female students can have more chances. of ...
1. Introduction. The World Health Organization [] estimates that 264 million people worldwide were suffering from an anxiety disorder and 322 million from a depressive disorder in 2015, corresponding to prevalence rates of 3.6% and 4.4%.While their prevalence varies slightly by age and gender [], they are among the most common mental disorders in the general population [2,3,4,5,6].
Econometric analysis of the relationship between vitamin D deficiency and depression was performed by Yunzhi et al. and Shauni et al. performed a bibliometric analysis of domestic and international research papers on depression-related genes from 2003 to 2007. A previous review of depression-related bibliometric studies revealed that there is ...
Cause and Effects of The Great Depression. The economic devastation of the 1920s led to the Great Depression and brought a tragedy for the whole society. Crash of stock market The crash of the stock market in 1929 ushered in the Great [ā¦] The Reality of the Great Depression in Steinbeck's "The Grapes of Wrath".
End with a period. In this title, only the words Social and A are capitalized. Example: Atteberry-Ash, B. (2022). Social work and social justice: A conceptual review. For the last component, you need the source. For an article, this is the title of the journal, volume, issue, which is sometimes called number, and page numbers of the article ...